NZ620485B2 - Ror gamma modulators - Google Patents
Ror gamma modulators Download PDFInfo
- Publication number
- NZ620485B2 NZ620485B2 NZ620485A NZ62048512A NZ620485B2 NZ 620485 B2 NZ620485 B2 NZ 620485B2 NZ 620485 A NZ620485 A NZ 620485A NZ 62048512 A NZ62048512 A NZ 62048512A NZ 620485 B2 NZ620485 B2 NZ 620485B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- independently
- hal
- coor
- conr
- Prior art date
Links
- 230000000051 modifying Effects 0.000 title claims description 21
- 201000010099 disease Diseases 0.000 claims abstract description 61
- 206010012601 Diabetes mellitus Diseases 0.000 claims abstract description 57
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 141
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 75
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 125000004043 oxo group Chemical group O=* 0.000 claims description 46
- 239000011780 sodium chloride Substances 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000003700 epoxy group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 21
- 230000002265 prevention Effects 0.000 claims description 18
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 206010022489 Insulin resistance Diseases 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 206010065941 Central obesity Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 206010011401 Crohn's disease Diseases 0.000 claims description 4
- 206010058108 Dyslipidaemia Diseases 0.000 claims description 4
- 208000009576 Hypercholesterolemia Diseases 0.000 claims description 4
- 206010062060 Hyperlipidaemia Diseases 0.000 claims description 4
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims description 4
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims description 4
- 208000001083 Kidney Disease Diseases 0.000 claims description 4
- 206010061227 Lipid metabolism disease Diseases 0.000 claims description 4
- 206010029149 Nephropathy Diseases 0.000 claims description 4
- 206010029151 Nephropathy Diseases 0.000 claims description 4
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 4
- 206010029331 Neuropathy peripheral Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010036049 Polycystic ovary Diseases 0.000 claims description 4
- 206010038932 Retinopathy Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 201000001320 atherosclerosis Diseases 0.000 claims description 4
- 201000010066 hyperandrogenism Diseases 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 200000000008 restenosis Diseases 0.000 claims description 4
- 201000010874 syndrome Diseases 0.000 claims description 4
- 201000006704 ulcerative colitis Diseases 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 229910003827 NRaRb Inorganic materials 0.000 claims 2
- 229910004664 ORa Inorganic materials 0.000 claims 2
- 229910003667 SRa Inorganic materials 0.000 claims 1
- 150000001828 cholane derivatives Chemical class 0.000 abstract description 3
- -1 oxo-) substituents Chemical group 0.000 description 94
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 76
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- 239000000203 mixture Substances 0.000 description 71
- 102000005962 receptors Human genes 0.000 description 65
- 108020003175 receptors Proteins 0.000 description 65
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 54
- 108090001061 Insulin Proteins 0.000 description 38
- 102000004877 Insulin Human genes 0.000 description 38
- 239000002904 solvent Substances 0.000 description 36
- 235000019439 ethyl acetate Nutrition 0.000 description 33
- 230000002401 inhibitory effect Effects 0.000 description 33
- 230000002829 reduced Effects 0.000 description 32
- 239000003112 inhibitor Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- 239000000556 agonist Substances 0.000 description 21
- 230000027455 binding Effects 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000003446 ligand Substances 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 238000003756 stirring Methods 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- AMXOYNBUYSYVKV-UHFFFAOYSA-M Lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 14
- 230000003042 antagnostic Effects 0.000 description 14
- 239000005557 antagonist Substances 0.000 description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
- 230000000875 corresponding Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000008079 hexane Substances 0.000 description 12
- 235000009200 high fat diet Nutrition 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 230000002194 synthesizing Effects 0.000 description 12
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 11
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 11
- 239000004380 Cholic acid Substances 0.000 description 11
- 229960002471 cholic acid Drugs 0.000 description 11
- 235000019416 cholic acid Nutrition 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 101710005817 RORC Proteins 0.000 description 9
- 239000003613 bile acid Substances 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 150000002118 epoxides Chemical class 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 7
- 108060001084 Luciferase family Proteins 0.000 description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- QSHQKIURKJITMZ-BRPMRXRMSA-N cholane group Polymers [C@@H]1(CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCC QSHQKIURKJITMZ-BRPMRXRMSA-N 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000018 receptor agonist Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 5
- 102000003797 Neuropeptides Human genes 0.000 description 5
- 108090000189 Neuropeptides Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- 230000001965 increased Effects 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 230000003000 nontoxic Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 4
- 102100017813 PTPN1 Human genes 0.000 description 4
- 108091007881 ROR receptors Proteins 0.000 description 4
- UNAANXDKBXWMLN-UHFFFAOYSA-N Sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 4
- 229960004793 Sucrose Drugs 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 150000002009 diols Chemical class 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 235000002864 food coloring agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000001264 neutralization Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000001603 reducing Effects 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- NZGALICACGXBQM-HOBHVFGFSA-N (2R)-5-(diaminomethylideneamino)-2-(3,3-dinaphthalen-1-ylpropanoylamino)-N-[(2S)-1-methoxy-3-phenylpropan-2-yl]pentanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@@H](COC)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)CC(C=1C2=CC=CC=C2C=CC=1)C=1C2=CC=CC=C2C=CC=1)C1=CC=CC=C1 NZGALICACGXBQM-HOBHVFGFSA-N 0.000 description 3
- 125000005917 3-methylpentyl group Chemical group 0.000 description 3
- MOIPGXQKZSZOQX-UHFFFAOYSA-N Carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920001268 Cholestyramine Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710042131 GCG Proteins 0.000 description 3
- 102100003818 GCG Human genes 0.000 description 3
- 101700071595 GRZ1 Proteins 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N Iron(III) oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229960003105 Metformin Drugs 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N Orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 241000242739 Renilla Species 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N Sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 101700078733 ZGLP1 Proteins 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000011759 adipose tissue development Effects 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N epoxyketone group Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 3
- 230000000640 hydroxylating Effects 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229960004034 sitagliptin Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- SYOKIDBDQMKNDQ-HHUWHTLVSA-N (2S)-1-[2-[[(5S,7R)-3-hydroxy-1-adamantyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C[C@H](C2)CC(C1)(C1)O)C21NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-HHUWHTLVSA-N 0.000 description 2
- ZSOPWZQRZHWYFY-NUXPJIRBSA-N (2S,3S)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC[C@H](C)[C@H](N)C(=O)N1CCSC1 ZSOPWZQRZHWYFY-NUXPJIRBSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 description 2
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 description 2
- RJRBRCCJETZJLT-GSICZYLSSA-N 1229U91 Chemical compound C([C@H](NC(=O)C1CNC(=O)CC[C@@H](C(=O)N2CCC[C@H]2C(=O)NC(CNC(=O)CC[C@@H](C(N2CCC[C@H]2C(=O)N1)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 RJRBRCCJETZJLT-GSICZYLSSA-N 0.000 description 2
- BKQCTMOROFZQNH-HSZRJFAPSA-N 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-5-phenylpentan-2-yl]propanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)CCC1=CC=CC=C1 BKQCTMOROFZQNH-HSZRJFAPSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 2
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5α-Androstane-3β,17β-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 description 2
- 101700081524 ACACB Proteins 0.000 description 2
- 102100011407 ACACB Human genes 0.000 description 2
- 101700045148 ACC2 Proteins 0.000 description 2
- 101700062069 AWAT1 Proteins 0.000 description 2
- 102100018926 AWAT1 Human genes 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N Allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 102000034341 BB3R Human genes 0.000 description 2
- KUWBXRGRMQZCSS-HSZRJFAPSA-N BIBP-3226 Chemical compound N([C@H](CCCN=C(N)N)C(=O)NCC=1C=CC(O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 KUWBXRGRMQZCSS-HSZRJFAPSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Clearol Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N Clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N Colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101700062901 DPP Proteins 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- 102100008329 FASN Human genes 0.000 description 2
- 101710008102 FASN Proteins 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N Fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 2
- 102000000393 Ghrelin Receptors Human genes 0.000 description 2
- 108010016122 Ghrelin Receptors Proteins 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 108010002059 Histamine receptors Proteins 0.000 description 2
- 102000000543 Histamine receptors Human genes 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229940031703 LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE Drugs 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- 229960004773 Losartan Drugs 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N Losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N Melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
- 108060004714 Melanin-concentrating hormone Proteins 0.000 description 2
- 102000010478 Melanin-concentrating hormone 1 receptor Human genes 0.000 description 2
- 108050001970 Melanin-concentrating hormone 1 receptor Proteins 0.000 description 2
- 102000017862 Melanin-concentrating hormone 2 receptor Human genes 0.000 description 2
- 108050007063 Melanin-concentrating hormone 2 receptor Proteins 0.000 description 2
- 102000001796 Melanocortin 4 receptor Human genes 0.000 description 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 2
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 2
- 229950001135 Muraglitazar Drugs 0.000 description 2
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N Nicotinyl alcohol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- 108070000031 Orphan receptors Proteins 0.000 description 2
- 102000016978 Orphan receptors Human genes 0.000 description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 102100003487 PDE3B Human genes 0.000 description 2
- 101700015521 PDE3B Proteins 0.000 description 2
- 102100002332 PYY Human genes 0.000 description 2
- 210000000496 Pancreas Anatomy 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N Phenethyl alcohol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N Phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N Probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- SSJGXNSABQPEKM-SBUIBGKBSA-N Pyy peptide Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 SSJGXNSABQPEKM-SBUIBGKBSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N Rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 229960004937 Saxagliptin Drugs 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 2
- YUJMJNYBGRTWCW-UHFFFAOYSA-N [SiH3]C([SiH3])=O Chemical compound [SiH3]C([SiH3])=O YUJMJNYBGRTWCW-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 230000003078 antioxidant Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 108010063504 bombesin receptor subtype 3 Proteins 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 150000001829 cholanes Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- LZXQXHKDCNQUOF-UHFFFAOYSA-N diethyl (2-oxochromen-7-yl) phosphate Chemical compound C1=CC(=O)OC2=CC(OP(=O)(OCC)OCC)=CC=C21 LZXQXHKDCNQUOF-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002641 glycemic Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 102400001132 melanin-concentrating hormone Human genes 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N methyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 101710031992 pRL90232 Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- 101710035540 plaa2 Proteins 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 230000000754 repressing Effects 0.000 description 2
- 108091008001 retinoid hormone receptors Proteins 0.000 description 2
- 102000027730 retinoid hormone receptors Human genes 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000707 stereoselective Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (1R,1'R)-2,2'-iminobis{1-[(2R,2'S)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]ethanol} Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- BHVGOYREXHCFOE-HRFSGMKKSA-N (1R,2R)-2-[2-(5,6-dihydrodibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)ethyl-methylamino]-1-phenylpropan-1-ol Chemical compound C1([C@@H](O)[C@@H](C)N(C)CC=C2C3=CC=CC=C3CCC3=CC=CC=C32)=CC=CC=C1 BHVGOYREXHCFOE-HRFSGMKKSA-N 0.000 description 1
- QGJUIPDUBHWZPV-VFGQHSGRSA-N (1R,3S,5R)-2-[(2S)-2-amino-2-[(5S,7R)-3-hydroxy-1-adamantyl]acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile Chemical compound C([C@@H](C1)C2)[C@@H](C3)CC1(O)CC23[C@H](N)C(=O)N1[C@H](C#N)C[C@H]2C[C@H]21 QGJUIPDUBHWZPV-VFGQHSGRSA-N 0.000 description 1
- UEZIBPZHJNOZNX-CDTKKYFSSA-N (2R,3R,4R,5S)-2-(hydroxymethyl)-1-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 UEZIBPZHJNOZNX-CDTKKYFSSA-N 0.000 description 1
- FOZFSEMFCIPOSZ-SPCKQMHLSA-N (2R,3R,4R,5S)-2-(hydroxymethyl)-1-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol;trihydrate Chemical compound O.O.O.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 FOZFSEMFCIPOSZ-SPCKQMHLSA-N 0.000 description 1
- AAKDPDFZMNYDLR-XZBKPIIZSA-N (2R,3R,4R,5S)-2-(hydroxymethyl)-1-methylpiperidine-3,4,5-triol Chemical compound CN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO AAKDPDFZMNYDLR-XZBKPIIZSA-N 0.000 description 1
- JVHNDORZQVXCHS-RWKVSTELSA-N (2R,3R,4S,5S)-2-(hydroxymethyl)-6-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-methoxyoxan-2-yl]piperidine-3,4,5-triol Chemical compound C1([C@@H]([C@@H](O)[C@H](O)[C@@H](CO)N1)O)[C@@]1(OC)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JVHNDORZQVXCHS-RWKVSTELSA-N 0.000 description 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N (2S)-2-(2-benzoylanilino)-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]propanoic acid Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 description 1
- LPUDGHQMOAHMMF-JBACZVJFSA-N (2S)-2-[[[(2S)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 description 1
- ZXEIEKDGPVTZLD-NDEPHWFRSA-N (2S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide Chemical compound O=C([C@@H](SCCCCCCCCCCCC)C=1C=CC=CC=1)NC1=CC(C)=C(O)C(C)=C1C ZXEIEKDGPVTZLD-NDEPHWFRSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- RVWNMGKSNGWLOL-GIIHNPQRSA-N (2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 1
- LRXXRIXDSAEIOR-ZDUSSCGKSA-N (2S)-N-[(2-chlorophenyl)methyl]-1-phenylpropan-2-amine Chemical compound C([C@H](C)NCC=1C(=CC=CC=1)Cl)C1=CC=CC=C1 LRXXRIXDSAEIOR-ZDUSSCGKSA-N 0.000 description 1
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- URRAHSMDPCMOTH-LNLFQRSKSA-N (2S,4S)-1-[(2S)-2-amino-3,3-bis(4-fluorophenyl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile Chemical compound C=1C=C(F)C=CC=1C([C@H](N)C(=O)N1[C@@H](C[C@H](F)C1)C#N)C1=CC=C(F)C=C1 URRAHSMDPCMOTH-LNLFQRSKSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 1
- JDKLPDJLXHXHNV-MFVUMRCOSA-N (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(N)=O)C1=CC=CC=C1 JDKLPDJLXHXHNV-MFVUMRCOSA-N 0.000 description 1
- DSMNGWOUQMYTJH-MBPVOVBZSA-N (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a-hydroxy-9-methoxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)OC)CC1CC1 DSMNGWOUQMYTJH-MBPVOVBZSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- REZGGXNDEMKIQB-UHFFFAOYSA-N 1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N 103890-78-4 Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- NXOLVMFMAFCDSR-UHFFFAOYSA-M 2-(chloromethyl)oxirane;prop-2-en-1-amine;N-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;chloride Chemical compound [Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C NXOLVMFMAFCDSR-UHFFFAOYSA-M 0.000 description 1
- TYZQFNOLWJGHRZ-UHFFFAOYSA-N 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine Chemical compound N=1CCNC=1CC(C=1N=CC=CC=1)C1=CC=CC=C1 TYZQFNOLWJGHRZ-UHFFFAOYSA-N 0.000 description 1
- NAXSRXHZFIBFMI-UHFFFAOYSA-N 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)azaniumyl]propoxy]phenyl]acetate Chemical compound OC(=O)CC1=CC=CC(OCCCN(CC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC=2C(=C(C=CC=2)C(F)(F)F)Cl)=C1 NAXSRXHZFIBFMI-UHFFFAOYSA-N 0.000 description 1
- ZGGNJJJYUVRADP-UHFFFAOYSA-N 2-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid Chemical compound C=1C=CC(Cl)=CC=1C(O)CNC(C)CC1=CC=C(OCC(O)=O)C=C1 ZGGNJJJYUVRADP-UHFFFAOYSA-N 0.000 description 1
- ACZKTJZXXSHIGF-UHFFFAOYSA-N 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylic acid Chemical compound C=1C=C(Cl)C=CC=1CCCCCC1(C(=O)O)CO1 ACZKTJZXXSHIGF-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- AGJJTKRYTPXPGM-UHFFFAOYSA-N 2-cyclohexyl-N-methylpropan-1-amine Chemical compound CNCC(C)C1CCCCC1 AGJJTKRYTPXPGM-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- DFZGGADKGZVOBJ-UHFFFAOYSA-N 2-methylhexane Chemical group CCCC[C](C)C DFZGGADKGZVOBJ-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-N-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-O-methyl 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N 3-acetyl-6-methylpyran-2,4-dione Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- SBJLJOFPWOYATP-XMMPIXPASA-N 3-amino-3-methyl-N-[(3R)-2-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]butanamide Chemical compound C([C@H](C1=O)NC(=O)CC(C)(N)C)CC2=CC=CC=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 SBJLJOFPWOYATP-XMMPIXPASA-N 0.000 description 1
- WZFZJEPHYDDFCT-UHFFFAOYSA-N 3-chloro-2-methyl-N-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 WZFZJEPHYDDFCT-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N 3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- BSFKAVCGRDMWTK-UHFFFAOYSA-N 5-(4-chlorophenyl)-N-[(4-chlorophenyl)sulfonylmethyl]-N'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C1C(C=2C=CC=CC=2)C(C=2C=CC(Cl)=CC=2)=NN1C(NC)=NCS(=O)(=O)C1=CC=C(Cl)C=C1 BSFKAVCGRDMWTK-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N 5-(7-(4-(4,5-DIHYDRO-2-OXAZOLYL)PHENOXY)HEPTYL)-3-METHYL ISOXAZOLE Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- WTOVRSWDBLIFHU-UHFFFAOYSA-N 5-O-methyl 3-O-propan-2-yl 2-(carbamoyloxymethyl)-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(COC(N)=O)=C(C(=O)OC(C)C)C1C1=CC=CC(Cl)=C1Cl WTOVRSWDBLIFHU-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 239000003406 5-lipoxygenase-activating protein inhibitor Substances 0.000 description 1
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 description 1
- VFFZWMWTUSXDCB-ZDUSSCGKSA-N 6-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VFFZWMWTUSXDCB-ZDUSSCGKSA-N 0.000 description 1
- 102100011470 ABCA4 Human genes 0.000 description 1
- 101700012451 ABCA4 Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229950002544 AMINOREX Drugs 0.000 description 1
- 229960002122 Acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N Acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960001466 Acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N Acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 102000019632 Acyl transferases Human genes 0.000 description 1
- 108091022082 Acyl transferases Proteins 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 229940083712 Aldosterone antagonists Drugs 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- VBZDETYCYXPOAK-OVCLIPMQSA-N Amfecloral Chemical compound ClC(Cl)(Cl)/C=N/C(C)CC1=CC=CC=C1 VBZDETYCYXPOAK-OVCLIPMQSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N Amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- SYAKTDIEAPMBAL-UHFFFAOYSA-N Aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- LVEXHFZHOIWIIP-UHFFFAOYSA-N Amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 description 1
- 229950010351 Amosulalol Drugs 0.000 description 1
- 229940025084 Amphetamine Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N Amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BHIAIPWSVYSKJS-UHFFFAOYSA-N Arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 1
- 229950010731 Arotinolol Drugs 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 229960002274 Atenolol Drugs 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 229950010046 Avasimibe Drugs 0.000 description 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 1
- 229950004646 Azelnidipine Drugs 0.000 description 1
- 108010041654 BIM 43073D Proteins 0.000 description 1
- 229960001035 BOPINDOLOL Drugs 0.000 description 1
- VXMOONUMYLCFJD-DHLKQENFSA-N Barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N Benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N Benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N Bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 Bepridil Drugs 0.000 description 1
- 229960002747 Betacarotene Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N Betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 229960003588 Bevantolol Drugs 0.000 description 1
- HXLAFSUPPDYFEO-UHFFFAOYSA-N Bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 1
- 229940096699 Bile acid sequestrants Drugs 0.000 description 1
- 229960002781 Bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N Bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N Bopindolol Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N Bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N Buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N Bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
- GVEZIHKRYBHEFX-NQQPLRFYSA-N CERULENIN Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
- UMQUQWCJKFOUGV-UHFFFAOYSA-N CGP 12177 Chemical compound CC(C)(C)NCC(O)COC1=CC=CC2=C1NC(=O)N2 UMQUQWCJKFOUGV-UHFFFAOYSA-N 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N CHEMBL511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- PHKYGBHARUTZOY-KTVVNDHVSA-N CKD-711 Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@]2(CO)O[C@@H]21)O)CO)[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O PHKYGBHARUTZOY-KTVVNDHVSA-N 0.000 description 1
- 229950000352 CLOMINOREX Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229950001261 Camiglibose Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N Candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N Caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 102000018208 Cannabinoid receptor family Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor family Proteins 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- KVLLHLWBPNCVNR-SKCUWOTOSA-N Capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229960001222 Carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N Carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N Carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DLNKOYKMWOXYQA-IONNQARKSA-N Cathine Chemical compound C[C@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-IONNQARKSA-N 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960002320 Celiprolol Drugs 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 229960002155 Chlorothiazide Drugs 0.000 description 1
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 1
- 229960001761 Chlorpropamide Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N Chlortalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 229940107084 Chlorthalidone Drugs 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 229960005025 Cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N Cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229950001653 Cilomilast Drugs 0.000 description 1
- 229950002934 Cilostamide Drugs 0.000 description 1
- UIAYVIIHMORPSJ-UHFFFAOYSA-N Cilostamide Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 UIAYVIIHMORPSJ-UHFFFAOYSA-N 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N Ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N Clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- UCAIEVHKDLMIFL-UHFFFAOYSA-N Clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 1
- TZWKUQDQKPYNLL-UHFFFAOYSA-N Cloforex Chemical compound CCOC(=O)NC(C)(C)CC1=CC=C(Cl)C=C1 TZWKUQDQKPYNLL-UHFFFAOYSA-N 0.000 description 1
- HAHOPPGVHWVBRR-UHFFFAOYSA-N Clominorex Chemical compound O1C(N)=NCC1C1=CC=C(Cl)C=C1 HAHOPPGVHWVBRR-UHFFFAOYSA-N 0.000 description 1
- 229950006376 Clomoxir Drugs 0.000 description 1
- HXCXASJHZQXCKK-UHFFFAOYSA-N Clortermine Chemical compound CC(C)(N)CC1=CC=CC=C1Cl HXCXASJHZQXCKK-UHFFFAOYSA-N 0.000 description 1
- 229950000649 Clortermine Drugs 0.000 description 1
- 229920002905 Colesevelam Polymers 0.000 description 1
- 229940097479 Colestid Drugs 0.000 description 1
- KLVRDXBAMSPYKH-RKYZNNDCSA-N Corticoliberin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
- 229940041967 Corticotropin-Releasing Hormone Drugs 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- QGJUIPDUBHWZPV-YQBUGCKMSA-N DB07465 Chemical compound C([C@@H](C1)C2)[C@@H](C3)C[C@@]1(O)C[C@]23[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-YQBUGCKMSA-N 0.000 description 1
- 229960005227 DELAPRIL Drugs 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- YZQLWPMZQVHJED-UHFFFAOYSA-N Dalcetrapib Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 description 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N Darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
- 229950006689 Darglitazone Drugs 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N Delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 229950010300 Denagliptin Drugs 0.000 description 1
- BADQRNHAZHSOKC-UHFFFAOYSA-N Deriglidole Chemical compound C1C(C2=3)=CC=CC=3CCN2C1(CCC)C1=NCCN1 BADQRNHAZHSOKC-UHFFFAOYSA-N 0.000 description 1
- 229950011527 Deriglidole Drugs 0.000 description 1
- 229960004597 Dexfenfluramine Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229940119750 Dextroamphetamine Drugs 0.000 description 1
- 102000016862 Dicarboxylic Acid Transporters Human genes 0.000 description 1
- 108010092943 Dicarboxylic Acid Transporters Proteins 0.000 description 1
- 229960004706 Dichlorphenamide Drugs 0.000 description 1
- GJQPMPFPNINLKP-UHFFFAOYSA-N Diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N Diethylethanolamine Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- UHZJPVXMMCFPNR-UHFFFAOYSA-N Difemetorex Chemical compound OCCN1CCCCC1C(C=1C=CC=CC=1)C1=CC=CC=C1 UHZJPVXMMCFPNR-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229940101029 Dipotassium Glycyrrhizinate Drugs 0.000 description 1
- 229960001389 Doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N Doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 102000002148 EC 2.3.1.20 Human genes 0.000 description 1
- 108010001348 EC 2.3.1.20 Proteins 0.000 description 1
- 108010000775 EC 2.3.3.10 Proteins 0.000 description 1
- 102000019622 EC 2.7.1.2 Human genes 0.000 description 1
- 108010021582 EC 2.7.1.2 Proteins 0.000 description 1
- 229950001184 ECADOTRIL Drugs 0.000 description 1
- 229950006213 ETOMOXIR Drugs 0.000 description 1
- ODUOJXZPIYUATO-LJQANCHMSA-N Ecadotril Chemical compound C([C@H](CSC(=O)C)C(=O)NCC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ODUOJXZPIYUATO-LJQANCHMSA-N 0.000 description 1
- 229950005925 Eflucimibe Drugs 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N Efonidipine Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- 229950003102 Efonidipine Drugs 0.000 description 1
- 229950000269 Emiglitate Drugs 0.000 description 1
- 229960000873 Enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- MVDXXGIBARMXSA-UHFFFAOYSA-N Englitazone Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(OC(CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-UHFFFAOYSA-N 0.000 description 1
- 229950002375 Englitazone Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N Eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N Etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960002541 Ethacrynic Acid Drugs 0.000 description 1
- YAGBSNMZQKEFCO-UHFFFAOYSA-N Etilamfetamine Chemical compound CCNC(C)CC1=CC=CC=C1 YAGBSNMZQKEFCO-UHFFFAOYSA-N 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N Etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N Ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229950002723 FLUDOREX Drugs 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N Farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 229950003707 Farglitazar Drugs 0.000 description 1
- 229960003580 Felodipine Drugs 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- BAQKJENAVQLANS-UHFFFAOYSA-N Fenbutrazate Chemical compound C=1C=CC=CC=1C(CC)C(=O)OCCN(C1C)CCOC1C1=CC=CC=C1 BAQKJENAVQLANS-UHFFFAOYSA-N 0.000 description 1
- 229960002533 Fenbutrazate Drugs 0.000 description 1
- 229960001582 Fenfluramine Drugs 0.000 description 1
- HEXAHJRXDZDVLR-HZPDHXFCSA-N Fenisorex Chemical compound C1([C@@H]2C3=CC(F)=CC=C3C[C@@H](O2)NC)=CC=CC=C1 HEXAHJRXDZDVLR-HZPDHXFCSA-N 0.000 description 1
- 229950000734 Fenisorex Drugs 0.000 description 1
- 229960002297 Fenofibrate Drugs 0.000 description 1
- IQUFSXIQAFPIMR-UHFFFAOYSA-N Fenproporex Chemical compound N#CCCNC(C)CC1=CC=CC=C1 IQUFSXIQAFPIMR-UHFFFAOYSA-N 0.000 description 1
- 238000006732 Fleming-Tamao oxidation reaction Methods 0.000 description 1
- CXLOIJUDIPVKOU-UHFFFAOYSA-N Fludorex Chemical compound CNCC(OC)C1=CC=CC(C(F)(F)F)=C1 CXLOIJUDIPVKOU-UHFFFAOYSA-N 0.000 description 1
- NMGYDYBWRZHLHR-UHFFFAOYSA-N Fluminorex Chemical compound O1C(N)=NCC1C1=CC=C(C(F)(F)F)C=C1 NMGYDYBWRZHLHR-UHFFFAOYSA-N 0.000 description 1
- 229950007852 Fluminorex Drugs 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- XSOUHEXVEOQRKJ-IUCAKERBSA-N Fluparoxan Chemical compound O1[C@H]2CNC[C@@H]2OC2=C1C=CC=C2F XSOUHEXVEOQRKJ-IUCAKERBSA-N 0.000 description 1
- 229950006702 Fluparoxan Drugs 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- DLGIIZAHQPTVCJ-UHFFFAOYSA-N Furfenorex Chemical compound C=1C=COC=1CN(C)C(C)CC1=CC=CC=C1 DLGIIZAHQPTVCJ-UHFFFAOYSA-N 0.000 description 1
- 229950005457 Furfenorex Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N Furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 Furosemide Drugs 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101700002119 GAL Proteins 0.000 description 1
- 229960000457 Gallopamil Drugs 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229950004781 Gemcabene Drugs 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 229960000346 Gliclazide Drugs 0.000 description 1
- BOVGTQGAOIONJV-UHFFFAOYSA-N Gliclazide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CC2CCCC2C1 BOVGTQGAOIONJV-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 Glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960003468 Gliquidone Drugs 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N Gliquidone Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229940095884 Glucophage Drugs 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 108091006272 Glucose transporter family Proteins 0.000 description 1
- 229940014653 Glyburide Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 102100017183 HMGCS1 Human genes 0.000 description 1
- 101710045397 HTR2C Proteins 0.000 description 1
- 102100002609 HTR2C Human genes 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N Humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 229960002474 Hydralazine Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N Hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010051161 Hyperglucagonaemia Diseases 0.000 description 1
- 229950001476 IDAZOXAN Drugs 0.000 description 1
- HPMRFMKYPGXPEP-UHFFFAOYSA-N Idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N Imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 229960004569 Indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N Indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229950008838 Indenolol Drugs 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N Indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 229960002056 Indoramin Drugs 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 229960002869 Insulin Glargine Drugs 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 229960002068 Insulin Lispro Drugs 0.000 description 1
- UBHYDQAARZKHEZ-UHFFFAOYSA-N Iodophenpropit Chemical compound C=1C=C(I)C=CC=1CCN=C(N)SCCCC1=CN=CN1 UBHYDQAARZKHEZ-UHFFFAOYSA-N 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N Irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229950011269 Isaglidole Drugs 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- SKRDXYBATCVEMS-UHFFFAOYSA-N Isopropyl nitrite Chemical compound CC(C)ON=O SKRDXYBATCVEMS-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229940090473 Januvia Drugs 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 229950001530 Lemildipine Drugs 0.000 description 1
- 229960004294 Lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N Lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N Levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- KWTSXDURSIMDCE-MRVPVSSYSA-N Levoamphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 description 1
- 229950004771 Levofacetoperane Drugs 0.000 description 1
- BKPLVPRTTWIDNL-ZIAGYGMSSA-N Levophacetoperane Chemical compound C([C@@H]1[C@H](OC(=O)C)C=2C=CC=CC=2)CCCN1 BKPLVPRTTWIDNL-ZIAGYGMSSA-N 0.000 description 1
- OPPLDIXFHYTSSR-YQFKSOGVSA-N Linogliride Chemical compound CN1CCC\C1=N/C(/N1CCOCC1)=N/C1=CC=CC=C1 OPPLDIXFHYTSSR-YQFKSOGVSA-N 0.000 description 1
- 229950004872 Linogliride Drugs 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N Lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 229960002394 Lisinopril Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium Ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N Lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Loniten Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229940063720 Lopid Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229960005170 MOEXIPRIL Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N Manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- XXVROGAVTTXONC-UHFFFAOYSA-N Mefenorex Chemical compound ClCCCNC(C)CC1=CC=CC=C1 XXVROGAVTTXONC-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- KBHMHROOFHVLBA-UHFFFAOYSA-N Metamfepramone Chemical compound CN(C)C(C)C(=O)C1=CC=CC=C1 KBHMHROOFHVLBA-UHFFFAOYSA-N 0.000 description 1
- 229950001413 Metamfepramone Drugs 0.000 description 1
- 229960002900 Methylcellulose Drugs 0.000 description 1
- 229950001332 Midaglizole Drugs 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N Milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960003632 Minoxidil Drugs 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N MolPort-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- ZLVARELBORDLAV-UHFFFAOYSA-N N-(4,5-dihydro-1H-imidazol-2-yl)-4-fluoro-1,3-dihydroisoindol-2-amine Chemical compound C1C=2C(F)=CC=CC=2CN1NC1=NCCN1 ZLVARELBORDLAV-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N N-(p-Tolylsulfonyl)-N'-butylcarbamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 description 1
- NSJYMFYVNWVGON-UHFFFAOYSA-N N-[2-[4-(cyclopentylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 description 1
- XWLVOJZVWRCRMD-OFNKIYASSA-N N-[5-[(1R)-2-[[(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide Chemical compound C1=C(O)C(NS(=O)(=O)C)=CC([C@@H](O)CN[C@H](CC=2C=CC=CC=2)C=2C=CC(OC(F)F)=CC=2)=C1 XWLVOJZVWRCRMD-OFNKIYASSA-N 0.000 description 1
- UULIGRNKXHCLQN-UHFFFAOYSA-N N-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 UULIGRNKXHCLQN-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-M N-phenylcarbamate Chemical class [O-]C(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-M 0.000 description 1
- 102100000774 NMU Human genes 0.000 description 1
- QQOBHTXYNMYKOL-DSXOWAILSA-N NPY3-36 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 QQOBHTXYNMYKOL-DSXOWAILSA-N 0.000 description 1
- 102100020059 NR1H4 Human genes 0.000 description 1
- 229910019443 NaSi Inorganic materials 0.000 description 1
- 229960004255 Nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N Nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229950005705 Naftopidil Drugs 0.000 description 1
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 Naltrexone Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N Nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000698 Nateglinide Drugs 0.000 description 1
- 108010008267 Nerve Growth Factors Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- 229960001783 Nicardipine Drugs 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 108070000019 Nicotinic acid receptor Proteins 0.000 description 1
- 229960004738 Nicotinyl Alcohol Drugs 0.000 description 1
- 229960001597 Nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 Nimodipine Drugs 0.000 description 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N Nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Nipradilol Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- 229950000754 Nipradilol Drugs 0.000 description 1
- 229960000227 Nisoldipine Drugs 0.000 description 1
- 229960005425 Nitrendipine Drugs 0.000 description 1
- PVHUJELLJLJGLN-UHFFFAOYSA-N Nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-UHFFFAOYSA-N 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N Nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 229960001073 Nomifensine Drugs 0.000 description 1
- 229960002748 Norepinephrine Drugs 0.000 description 1
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Nucynt Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N Obedrex Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N Omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 Omapatrilat Drugs 0.000 description 1
- 102400000319 Oxyntomodulin Human genes 0.000 description 1
- 101800001388 Oxyntomodulin Proteins 0.000 description 1
- 229940097241 POTASSIUM-SPARING DIURETICS Drugs 0.000 description 1
- 229940116369 Pancreatic lipase Drugs 0.000 description 1
- 102000019280 Pancreatic lipase Human genes 0.000 description 1
- 108050006759 Pancreatic lipase Proteins 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N Penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- UMWAUEZOGHNSCH-UHFFFAOYSA-N Pentorex Chemical compound CC(N)(C)C(C)C1=CC=CC=C1 UMWAUEZOGHNSCH-UHFFFAOYSA-N 0.000 description 1
- 229960001476 Pentoxifylline Drugs 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 229960002582 Perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N Perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- 229960000436 Phendimetrazine Drugs 0.000 description 1
- 229960003243 Phenformin Drugs 0.000 description 1
- OOBHFESNSZDWIU-UHFFFAOYSA-N Phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
- 229960003209 Phenmetrazine Drugs 0.000 description 1
- 229960003562 Phentermine Drugs 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 102000016462 Phosphate Transport Proteins Human genes 0.000 description 1
- 108010092528 Phosphate Transport Proteins Proteins 0.000 description 1
- PZJBWSQQDMRZHY-UHFFFAOYSA-N Picilorex Chemical compound CC1NC(C2CC2)CC1C1=CC=C(Cl)C=C1 PZJBWSQQDMRZHY-UHFFFAOYSA-N 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N Pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M Potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229950004891 Pranidipine Drugs 0.000 description 1
- 239000005477 Pratosartan Substances 0.000 description 1
- 229950005649 Pratosartan Drugs 0.000 description 1
- 229960002965 Pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960001289 Prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N Prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N Propanamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- WNWALBVQAAIULR-UHFFFAOYSA-N Proxyfan Chemical class C=1N=CNC=1CCCOCC1=CC=CC=C1 WNWALBVQAAIULR-UHFFFAOYSA-N 0.000 description 1
- 229940073095 Questran Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N Quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- FLSLEGPOVLMJMN-YSSFQJQWSA-N Quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 1
- 108091008002 RAR-related orphan receptors Proteins 0.000 description 1
- 102100000775 REN Human genes 0.000 description 1
- 229960003401 Ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N Ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 229940116238 Revex Drugs 0.000 description 1
- RXSVYGIGWRDVQC-UHFFFAOYSA-N Rhc80267 Chemical compound C1CCCCC1=NOC(=O)NCCCCCCNC(=O)ON=C1CCCCC1 RXSVYGIGWRDVQC-UHFFFAOYSA-N 0.000 description 1
- 229960000764 Rilmenidine Drugs 0.000 description 1
- CQXADFVORZEARL-UHFFFAOYSA-N Rilmenidine Chemical compound C1CC1C(C1CC1)NC1=NCCO1 CQXADFVORZEARL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 Rimonabant Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229940085605 Saccharin Sodium Drugs 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- UAWABSHMGXMCRK-UHFFFAOYSA-L Samarium(II) iodide Chemical compound I[Sm]I UAWABSHMGXMCRK-UHFFFAOYSA-L 0.000 description 1
- 229950001780 Sampatrilat Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 Sertraline Drugs 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000002356 Skeleton Anatomy 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N Sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 229960002370 Sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N Sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- HRWCVUIFMSZDJS-SZMVWBNQSA-N Spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N Spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 1
- 108020003891 Squalene Monooxygenase Proteins 0.000 description 1
- 240000001132 Stevia rebaudiana Species 0.000 description 1
- 229940098466 Sublingual Tablet Drugs 0.000 description 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 description 1
- ODKDMMTXTVCCLJ-BVSLBCMMSA-N TMC-2-A Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N3[C@@H](CC4=CC(O)=C(C(=C4C3)O)OC)C(=O)N[C@@H](CC(CO)CO)C(O)=O)=CNC2=C1 ODKDMMTXTVCCLJ-BVSLBCMMSA-N 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229950002139 Talsupram Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N Tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- RMMXLENWKUUMAY-UHFFFAOYSA-N Telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 1
- 229950001790 Tendamistat Drugs 0.000 description 1
- 229960001693 Terazosin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N Terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229950000584 Tezosentan Drugs 0.000 description 1
- 229960004559 Theobromine Drugs 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- CVWILQHZFWRYPB-UHFFFAOYSA-N Tiamenidine Chemical compound CC1=CSC(Cl)=C1NC1=NCCN1 CVWILQHZFWRYPB-UHFFFAOYSA-N 0.000 description 1
- TWVUMMQUXMYOOH-UHFFFAOYSA-N Tilisolol Chemical compound C1=CC=C2C(=O)N(C)C=C(OCC(O)CNC(C)(C)C)C2=C1 TWVUMMQUXMYOOH-UHFFFAOYSA-N 0.000 description 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N Tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
- 229950004437 Tiqueside Drugs 0.000 description 1
- 229960002277 Tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N Tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N Torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 Torcetrapib Drugs 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 229950002223 Trecadrine Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- 229960001288 Triamterene Drugs 0.000 description 1
- 229940055755 Tricor Drugs 0.000 description 1
- YNZXWQJZEDLQEG-UHFFFAOYSA-N Trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triurene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N Troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- 102100001433 VIPR2 Human genes 0.000 description 1
- 101700031564 VIPR2 Proteins 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N Valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N Vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 229940002552 Xenical Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N Zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N Zonegran Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- PWDLDBWXTVILPC-QGGVPXFVSA-N [(3aS,5aR,8aR)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5',3'-d]pyran-3a-yl]methyl sulfamate;2-methyl-1-phenylpropan-2-amine Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)OC2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-QGGVPXFVSA-N 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N [2,6-di(propan-2-yl)phenyl] N-[2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]sulfamate Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- HGMSJMJPXGGEBP-UHFFFAOYSA-N [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium Chemical compound C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 HGMSJMJPXGGEBP-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000035507 absorption Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- OVMHABLOXWFPMV-UHFFFAOYSA-N acetyloxycarbonyl acetate Chemical compound CC(=O)OC(=O)OC(C)=O OVMHABLOXWFPMV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960002734 amfetamine Drugs 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 229950007556 aranidipine Drugs 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 229960002992 barnidipine Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N benzazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940076810 beta Sitosterol Drugs 0.000 description 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
- OENHQHLEOONYIE-VYAWBVGESA-N beta-Carotene Natural products CC=1CCCC(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-VYAWBVGESA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- 229940058933 biguanide antimalarials Drugs 0.000 description 1
- 229940090145 biguanide blood glucose lower drugs Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 229940090127 blood glucose lowering Alpha glucosidase inhibitors Drugs 0.000 description 1
- 229940090129 blood glucose lowering drugs Thiazolidinediones Drugs 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 229960002467 bunazosin Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 230000002149 cannabinoid Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960003609 cathine Drugs 0.000 description 1
- 101710027380 cck-a Proteins 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 229950005984 cerulenin Drugs 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KWYZNESIGBQHJK-UHFFFAOYSA-N chloro-dimethyl-phenylsilane Chemical compound C[Si](C)(Cl)C1=CC=CC=C1 KWYZNESIGBQHJK-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229930002875 chlorophylls Natural products 0.000 description 1
- 229950007046 chlorphentermine Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 150000001838 cholestanes Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 230000001886 ciliary Effects 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- 229960002492 clobenzorex Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 229950008294 cloforex Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229960001152 colesevelam Drugs 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000000950 dibromo group Chemical group Br* 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229950011229 difemetorex Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- FUZBPOHHSBDTJQ-CFOQQKEYSA-L disodium;5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate Chemical compound [Na+].[Na+].C1([C@@H](O)CN[C@@H](CC=2C=C3OC(OC3=CC=2)(C([O-])=O)C([O-])=O)C)=CC=CC(Cl)=C1 FUZBPOHHSBDTJQ-CFOQQKEYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- HTWFXPCUFWKXOP-UHFFFAOYSA-N dl-Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 description 1
- DWHHIPIOLSXJLV-UHFFFAOYSA-N dodecyl 2-aminopropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)N DWHHIPIOLSXJLV-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- DZLOHEOHWICNIL-UHFFFAOYSA-N ethyl 2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound C=1C=C(Cl)C=CC=1OCCCCCCC1(C(=O)OCC)CO1 DZLOHEOHWICNIL-UHFFFAOYSA-N 0.000 description 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N ethyl[(2S)-1-[3-(trifluoromethyl)phenyl]propan-2-yl]amine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- 229960001003 etilamfetamine Drugs 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 229960005231 fenproporex Drugs 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229950008402 glisentide Drugs 0.000 description 1
- 229950005319 glisolamide Drugs 0.000 description 1
- 239000003635 glucocorticoid antagonist Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 108010070965 hexarelin Proteins 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000035880 hyperglucagonemia Effects 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 229910000460 iron oxide Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229950005223 levamfetamine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 108010044655 lysylproline Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960001468 mefenorex Drugs 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- IVAQJHSXBVHUQT-ZVHZXABRSA-N methyl (E)-3-(3,5-dimethoxyphenyl)-2-[4-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]phenyl]prop-2-enoate Chemical compound C=1C=C(OC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)C=CC=1/C(C(=O)OC)=C\C1=CC(OC)=CC(OC)=C1 IVAQJHSXBVHUQT-ZVHZXABRSA-N 0.000 description 1
- LPDGLMPJFGGZGN-UHFFFAOYSA-N methyl 2-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate;hydrobromide Chemical compound Br.C1=CC(OCC(=O)OC)=CC=C1CC(C)NCC(O)C1=CC=CC(Cl)=C1 LPDGLMPJFGGZGN-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000003228 microsomal Effects 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 229960003938 moxonidine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 108010021512 neuromedin U Proteins 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000000269 nucleophilic Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 210000004923 pancreatic tissues Anatomy 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950000821 pentorex Drugs 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N phytanic acid Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- 229950003624 picilorex Drugs 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 229940096700 plain lipid modifying drugs Fibrates Drugs 0.000 description 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- KCTFTBCZZUBAKN-UHFFFAOYSA-N pratosartan Chemical compound CCCC1=NC=2CCCCC(=O)C=2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KCTFTBCZZUBAKN-UHFFFAOYSA-N 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 229960001007 quinaprilat Drugs 0.000 description 1
- 229960002281 racecadotril Drugs 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000000580 secretagogue Effects 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960002909 spirapril Drugs 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 108010037401 tendamistate Proteins 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003352 tertatolol Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229950000164 tiamenidine Drugs 0.000 description 1
- 229950008411 tilisolol Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229960002070 torsemide Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 229960002906 trimazosin Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 101700023654 vib-1 Proteins 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229950005371 zaprinast Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N β-Sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Abstract
Provided is the use of polyhydroxylated cholane derivatives of formula II or IIa, wherein the variables are as defined in the specification, for the manufacture of a medicament for the treatment of type II diabetes and diseases, disorders and conditions which are related to type II diabetes, such as hyperglycemia. An example of the derivatives is 1beta,3alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholan-24-oate. hyperglycemia. An example of the derivatives is 1beta,3alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholan-24-oate.
Description
ROR gamma modulators
Field of the Invention
The present invention relates to compounds for use in the treatment or prevention, suppression or
amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in
particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of
production of such compounds, as well as methods of treatment or prevention of such diseases.
Background
Worldwide, there are about 250 million people that suffer from diabetes (type I and type II) and
the number is projected to double in next two decades. Type 1 diabetes is based on lack of
insulin production by the pancreas. Although the causes are not entirely known, type 1 diabetes
is a multi-factorial autoimmune disease that results from the specific and progressive destruction
of insulin producing beta-cells in the pancreas. Typical treatment of type 1 diabetes includes
(multiple) administration of insulin, which however does not cure diabetes or prevent its eventual
effects such as kidney failure, blindness, nerve damage, amputations, heart attack and stroke.
Even with insulin treatment, type 1 diabetes usually results in a drastic reduction in quality of life
and shortens the average life span by 15 years. Type 2 diabetes, also called non-insulin
dependent diabetes mellitus, is is a heterogeneous disease characterized by abnormalities in
carbohydrate and fat metabolism. The causes of type 2 diabetes are multi-factorial and include
both genetic and environmental elements that affect beta-cell function and insulin sensitivity in
tissues such as muscle, liver, pancreas and adipose tissue. As a consequence impaired insulin
secretion is observed and paralleled by a progressive decline in beta-cell function and chronic
insulin resistance. The inability of the endocrine pancreas to compensate for peripheral insulin
resistance leads to hyperglycaemia and onset of clinical type 2 diabetes characterized by
hyperglycemia, insulin resistance, absolute or relative insulin deficiency, hyperglucagonemia,
and increased hepatic glucose production. However, there is still no definitive treatment for the
disease.
Applicants have now surprisingly found that the retinoid-receptor related orphan receptors
(ROR) may act as a central regulator of adipogenesis. The retinoid-receptor related orphan
receptors consist of three family members, namely ROR alpha (Becker-Andree, Biochem.
Biophys. Res. Commun. 1993, 194:1371), ROR beta (Andre et al., Gene 1998, 516:277) and
ROR gamma (He et al, Immunity 1998, 9:797) and constitute the NR1F (ROR /RZR) subgroup
of the nuclear receptor superfamily (Mangelsdorf et al., Cell 1995, 83:835). Applicants have
shown that in particular the ROR gamma receptor, which has been linked exclusively to
immunological functions, may inhibit adipogenesis and may allow protection from diet or
genetically induced insulin resistance.
Thus the present specification describes compounds, in particular compounds based on a
polyhydroxylated cholane skeleton, that are able to act as ROR (gamma) receptor modulators or
ligands, thereby influencing the biological pathways in adipogenesis controlled by ROR
(gamma), and thus may be useful for the prevention, treatment and amelioration of diabetes and
diabetes-related disorders, in particular type II diabetes.
Summary of the Invention
The present invention relates in a first aspect to use of a compound having formula II or a
formula IIa and pharmaceutically acceptable salt or stereoisomers thereof, in the manufacture of
a medicament for the treatment or prevention of disorders, diseases or conditions responsive to
the modulation of the ROR gamma receptor, which are type II diabetes and diseases, disorders
and conditions that are related to type II diabetes, selected from hyperglycemia, low glucose
tolerance, insulin resistance, obesity, lipid disorders, dyslipidemia, hyperlipidemia,
hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis,
vascular restenosis, irritable bowel syndrome, inflammatory bowel disease, including Crohn's
disease and ulcerative colitis, other inflammatory conditions, pancreatitis, abdominal obesity,
neurodegenerative disease, retinopathy, nephropathy, neuropathy, Syndrome X, and ovarian
hyperandrogenism (polycystic ovarian syndrome), in a subject in need thereof,
II IIa
wherein
R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
1 2 a a a b a a b
wherein R and R are independently of each other H or (C1-6)alkyl, or R , R form
a b 1 2
together with the C-atoms to which they are linked an epoxy group;
R is H, hal,
R , R , R , R , are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
3 4 5 6 a a a b a a b
oxo, thio wherein R and R are independently of each other H or (C1-6)alkyl;
L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted or substituted by at
least one CN, hal, OH, NR R , COOR , NO , and wherein one or more of the non-
a b a 2
adjacent CH groups may independently be replaced by a group selected from –O-, -CO-,
-CO-O-, -O-CO-, -NR -, -NR -CO-, -CO-NR -, -CH=CH-, -C≡C-, wherein R and R are
a a a a b
independently of each other H or C(1-6)alkyl,
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of
a a a b c a c a b
each other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-
c 2 n 2 a
(CH ) -SO R , wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
2 p 3 a a
m is 0 to 5, and wherein
R and R are –OR , wherein R is H or C(1-6)alkyl.
3 6 a a
Also described are compounds based on a polyhydroxylated cholane skeleton and
pharmaceutically acceptable salts or stereoisomers thereof for use as modulators of the ROR
receptor, in particular, as selective ROR gamma receptor ligands (also hereinafter called
compounds of the invention or ROR gamma receptor ligands or modulators of the present
invention) having the general formula I
wherein
R , R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
2’ a a a b a a b
wherein R and R are independently of each other H or (C1-6)alkyl, or R , R form together
a b 1 2
with the C-atoms to which they are linked an epoxy group;
R , R , R , R , are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -
3 4 5 6
a a a b a
CONR R , oxo, thio wherein R and R are independently of each other H or (C1-6)alkyl;
a b a b
R , R , R are independently of each other H, (C1-10)alkyl, wherein one or more non
7 8 9
neighbouring CH groups may be replaced with -O-, -S-, -CO-, -CO-O-, -O-CO-, –NR -, -CO-
NR -, –NR -CO-, -C=C-, or -C≡C-; wherein R is H or (C1-6)alkyl;
a a a
L is a linking group, such as straight-chain or branched C(1-12)alkyl, which is unsubstituted or
substituted by at least one CN, hal, OH, NR R , COOR , NO , and wherein one or more of the
a b a 2
non-adjacent CH groups may independently be replaced by a group selected from –O-, -CO-, -
CO-O-, -O-CO-, -NR -, -NR -CO-, -CO-NR -, -CH=CH-, -C≡C-, wherein R and R are
a a a a b
independently of each other H or C(1-6)alkyl,
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
m is 0 to 5.
In specific embodiments, the compounds described herein are based on a polyhydroxylated
cholane skeleton having a –L-X- substituent at C17, and wherein the hydroxyl (or oxo-)
substituents are preferably in one or more positions selected from C1, C3, C6, C7, C12, more
preferably wherein the hydroxyl (or oxo-) substituents are at a total of three or four positions
selected from C1, C3, C6, C7, C12, most preferably wherein the hydroxyl (or oxo-) substituents
are at a total of three or four positions selected from C1, C3, C6, C7, C12 of which one hydroxyl
(or oxo-substituent) is in position C1 or C6.
Preferred compounds have three hydroxyl (or oxo-substituents) at positions C1, C3 and C7; C1,
C3 and C12; C1, C7 and C12; C3, C6 and C7; C3, C6 and C12; C6, C7 and C12; C1, C3 and C6;
C1, C6 and C7; and C1, C6, and C12.
Other preferred compounds have four hydroxyl (or oxo-substituents) at positions C1, C3, C7 and
C12; C3, C6, C7 and C12; C1, C3, C6 and C7; C1, C3, C6 and C12; and C1, C6, C7 and C12.
Also described are compounds of formula II and pharmaceutically acceptable salts or
stereoisomers thereof, preferably its stereoisomeric form IIa,
II IIa
wherein
R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
1 2 a a a b a a b
wherein R and R are independently of each other H or (C1-6)alkyl, or R , R form together
with the C-atoms to which they are linked an epoxy group;
R , R , R , R , are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -
3 4 5 6 a a a b a
CONR R , oxo, thio wherein R and R are independently of each other H or (C1-6)alkyl;
a b a b
R is H or hal,
L is a linking group, such as straight-chain or branched C(1-12)alkyl, which is unsubstituted or
substituted by at least one CN, hal, OH, NR R , COOR , NO , and wherein one or more of the
a b a
non-adjacent CH groups may independently be replaced by a group selected from –O-, -CO-, -
CO-O-, -O-CO-, -NR -, -NR -CO-, -CO-NR -, -CH=CH-, -C≡C-, wherein R and R are
a a a a b
independently of each other H or C(1-6)alkyl,
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
m is 0 to 5.
In one preferred embodiment, at least three, preferably three or four, groups selected from R ,
R , R , R and R are -OR or oxo, wherein R is H or C(1-6)alkyl.
3 4 5 6 a a
In another preferred embodiment, R and/or R are –OR or oxo.
1 4 a
More specifically, the compounds described herein are characterized by formula I, II or IIa,
wherein either (i) R and R are –OR , or (ii) R and R are –OR , or (iii) R is either –OR or
4 6 a 1 6 a 3 a
oxo and R is –OR , or (iv) R and R are –OR, and the remaining groups in each of the
6 a 5 6
compounds have the following meaning (where applicable):
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H, -OR , -NR R , wherein R
a a a b a a b a a b a
and R are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-
b 1 2
atoms to which R , R are linked to an epoxy group;
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H or hal, wherein R and R
a a a b a a b a b
are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-atoms
to which R , R are linked to an epoxy group;
R , R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
3 4 5 a a a b a a b
oxo, thio, preferably H, oxo, -OR , -NR R , wherein R and R are independently of each other
a a b a b
H or (C1-6)alkyl;
R is H or hal,
L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one or more
of the non-adjacent CH groups may independently be replaced by a group selected from –O-, -
CO-, - CO-O;
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
m is 0 to 5.
Also described are compounds of formula IV and V (with R being –OR or oxo) and
pharmaceutically acceptable salts or stereoisomers thereof,
R O OR
O OR
IV V
wherein
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H, -OR , -NR R , wherein R
a a a b a a b a a b a
and R are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-
b 1 2
atoms to which R1, R2 are linked to an epoxy group;
R is H or hal, or R forms together with R and the C-atoms to which R , R are linked to an
2 2 1 1 2
epoxy group;
R is H or hal,
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo, thio, preferably H, oxo, -OR , -
4 a a a b a a b a
NR R , wherein R and R are independently of each other H or (C1-6)alkyl,
a b a b
L is a straight-chain or branched C(1-12)alkyl;
X is H, -OR , –COOR , -CONR R , wherein R is H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -
a c a c
NH-(CH ) -CO R or -NH-(CH ) -SO R , wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl,
2 n 2 a 2 p 3 a a
R is H or C(1-6)alkyl, and
m is 0 to 5.
Also described are methods relating to convenient and efficient methods of synthesis of the
compounds described herein.
Also described are pharmaceutical compositions comprising at least one compound described
herein and a pharmaceutically acceptable carrier, and optionally at least one further
therapeutically active agent.
Also described are methods for the treatment or prevention of disorders, diseases, or conditions
responsive to the modulation of the ROR gamma receptor in a mammal in need thereof, in
particular diabetes and diabetes-related disorders, specifically type II diabetes, by administering
at least one compound (or a pharmaceutical composition thereof) described herein.
Also described are kits comprising at least one compound described herein (or a pharmaceutical
composition thereof).
Brief Description of Figures
Figure 1. Schematic of the luciferase activity assay
Figure 2: Inhibition of RORgamma activity (RI = relative inhibition; Conc = concentration of
1β,3α,7α,12α-tetrahydroxy-5β-cholanoate (tetraol) in nM).
Figure 3: Effect on insulin sensitivity in mice that were fed a high fat diet in combination with
different supplements at different concentrations. The y-axis represents relative glucose levels,
the x-axis represents time after insulin injection in min. The high fat diet was given as such (E)
or supplemented with tetraol 0.1% (A) or tetraol 0.01% (B) or cholic acid 0.1% (C) or cholic
acid 0.01% (D).
Figure 4: Effect of tetraol compound and cholic acid as control compound on glucose levels in
obese/insulin resistant mice over time (x-axis represents mM glucose, y-axis represents time
points of 6 and 12 weeks, striped bars represent fasted mice, filled bars represent fed mice).
Figure 5: Effect of tetraol compound and cholic acid as control compound on insulin levels in
obese/insulin resistant mice over time (x-axis represents pg/ml Insulin, y-axis represents time
points of 6 and 12 weeks, striped bars represent fasted mice, filled bars represent fed mice).
Detailed Description of the Invention
Unless specified otherwise, the following terms have the indicated meanings:
The term "subject” means a mammal, such as a human or an animal, being either male or female,
preferably a human.
The term “ligand” or “modulator” refers to a natural or synthetic compound which binds a
receptor molecule to form a receptor-ligand complex. The term ligand may include agonists,
antagonists, and compounds with partial agonist/antagonist action. An “agonist” is a natural or
synthetic compound which binds the receptor to form a receptor-agonist complex thereby
activating said receptor, initiating a pathway signaling and further biological processes. By
“antagonist” is meant a natural or synthetic compound that has a biological effect opposite to that
of an agonist. An antagonist binds the receptor and blocks the action of a receptor agonist. The
term “ligand” or “modulator”, when used according to the present invention in combination with
e.g. a ROR (gamma) receptor, refers to a(n) (endogenous) compound that can interact with a
ROR (gamma) receptor and initiate a pharmacological or biochemical response.
The term "binding affinity" refers to the ability of a compound to bind to its biological target. For
the present invention, it refers to the ability of a compound described herein, to bind to the ROR
(gamma) receptor.
The term "efficacy" describes the relative intensity of response induced by a compound when
binding to its receptor. Maximal response depends on the efficiency of coupling to the receptor.
The term "diabetes” as used herein includes both insulin-dependent diabetes mellitus (i.e.,
IDDM, also known as type I diabetes) and non-insulin-dependent diabetes mellitus (i.e.,
NIDDM, also known as type II diabetes). Type I diabetes, or insulin-dependent diabetes, is the
result of an absolute deficiency of insulin, the hormone which regulates glucose utilization. Type
II diabetes, or insulin-independent diabetes (i.e., non-insulin-dependent diabetes mellitus), often
occurs in the face of normal, or even elevated levels of insulin and appears to be the result of the
inability of tissues to respond appropriately to insulin. The compounds and compositions
described herein may be useful for treating both type I and type II diabetes, but may be
especially effective for treating type II diabetes (as shown hereinafter).
The term "diabetes related disorders" as used herein includes diseases, disorders and conditions
that are related to type 1 and type 2 diabetes, in particular diseases, disorders and conditions that
are related to type 2 diabetes, and therefore may be treated, controlled or in some cases
prevented, by administration of the compounds and compositions described herein. Diabetes
related disorders include e.g. hyperglycemia, low glucose tolerance, insulin resistance, obesity,
lipid disorders, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low
HDL levels, high LDL levels, atherosclerosis, vascular restenosis, irritable bowel syndrome,
inflammatory bowel disease, including Crohn's disease and ulcerative colitis, other inflammatory
conditions, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, nephropathy,
neuropathy, Syndrome X, ovarian hyperandrogenism (polycystic ovarian syndrome), and other
disorders where insulin resistance is a contributive component.
“Treatment” of diabetes according to the present disclosure refers to the administration of at least
one compound described herein to treat diabetes and diabetes-related disorders as defined herein,
e.g. in a subject in need thereof, e.g. a diabetic subject. Possible outcomes of such treatment may
be decreasing the glucose level in a subject with elevated glucose levels and/or improving
glycemic control and/or decreasing insulin levels in a subject with elevated insulin levels and/or
to reduce an increased plasma glucose concentration and/or to reduce an increased insulin
concentration and/or to reduce an increased blood triglyceride concentration and/or to increase
insulin sensitivity and/or enhancing glucose tolerance in a subject with glucose intolerance
and/or to reduce insulin resistance and/or to lower plasma insulin levels and/or an improvement
in glycemic control, particularly in type 2 diabetes.
“Prevention” (or “prophylaxis”) of diabetes according to the disclosure refers to the
administration of at least one compound described herein to prevent or treat the onset of diabetes
and diabetes-related disorders as defined herein in a subject in need thereof, e.g. a prediabetic
subject.
The term "subject" as used herein refers to an animal, preferably a mammal, most preferably a
human.
The term “polyhydroxylated cholane skeleton” includes in particular polyhydroxylated
cholestanes and more specifically polyhydroxylated bile acids. A polyhydroxylated cholane or
bile acid compound described herein includes, but is not limited to, from trihydroxylated,
tetrahydroxylated, pentahydroxylated, hexahydroxylated bile acids, etc., up to the maximal
hydroxylation level, but preferably (at least) trihydroxylated and (at least) tetrahydroxylated bile
acids. The term “bile acid” encompasses all naturally occurring (chemically synthesized) bile
acids (whether from man or from another animal) including conjugates thereof (e.g. in particular
conjugates with glycine, taurine and possibly other amino acids), as well as synthetic or semi-
synthetic analogs. Most naturally occurring bile acids are characterized by hydroxyl groups in
the A, B, and C ring of the cholane skeleton, predominantly at one or more of positions C3, C7,
C12, possibly (but more unusual) at positions C1, C6 and others. The junction of rings A and B
in the cholane skeleton (and in bile acids) exists in two isomeric forms, i.e. the C5- and C8-
substituents are cis (5-beta-cholane) or trans (5-alpha-cholane) configured. For the compounds
described herein, if not specified differently, both the alpha- and beta-isomer of the A/B-ring
junction are contemplated, preferably the beta-isomer.
The term “comprising” as used in this specification and claims means “consisting at least in part
of”. When interpreting statements in this specification, and claims which include the term
“comprising”, it is to be understood that other features that are additional to the features prefaced
by this term in each statement or claim may also be present. Related terms such as “comprise”
and “comprised” are to be interpreted in similar manner.
The present invention relates in a first aspect to a use to use of a compound having formula II or
a formula IIa and pharmaceutically acceptable salt or stereoisomers thereof, in the manufacture
of a medicament for the treatment or prevention of disorders, diseases or conditions responsive
to the modulation of the ROR gamma receptor, which are type II diabetes and diseases, disorders
and conditions that are related to type II diabetes, selected from hyperglycemia, low glucose
tolerance, insulin resistance, obesity, lipid disorders, dyslipidemia, hyperlipidemia,
hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis,
vascular restenosis, irritable bowel syndrome, inflammatory bowel disease, including Crohn's
disease and ulcerative colitis, other inflammatory conditions, pancreatitis, abdominal obesity,
neurodegenerative disease, retinopathy, nephropathy, neuropathy, Syndrome X, and ovarian
hyperandrogenism (polycystic ovarian syndrome), in a subject in need thereof,
II IIa
wherein
R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
1 2 a a a b a a b
wherein R and R are independently of each other H or (C1-6)alkyl, or R , R form
a b 1 2
together with the C-atoms to which they are linked an epoxy group;
R is H, hal,
R , R , R , R , are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
3 4 5 6 a a a b a a b
oxo, thio wherein R and R are independently of each other H or (C1-6)alkyl;
L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted or substituted by at
least one CN, hal, OH, NR R , COOR , NO , and wherein one or more of the non-
a b a 2
adjacent CH groups may independently be replaced by a group selected from –O-, -CO-,
-CO-O-, -O-CO-, -NR -, -NR -CO-, -CO-NR -, -CH=CH-, -C≡C-, wherein R and R are
a a a a b
independently of each other H or C(1-6)alkyl,
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of
a a a b c a c a b
each other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-
c 2 n 2 a
(CH ) -SO R , wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
2 p 3 a a
m is 0 to 5, and wherein
R and R are –OR , wherein R is H or C(1-6)alkyl.
3 6 a a
Also described are compounds for use as modulators of the ROR receptor, in particular, as
selective ROR gamma receptor ligands, having the general formula I or pharmaceutically
acceptable salts or stereoisomers thereof (numbering according to IUPAC nomenclature rules is
indicated)
wherein
R , R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
1 2 2’ a a a b a a b
wherein R and R are independently of each other H or (C1-6)alkyl, or R , R form together
with the C-atoms to which they are linked an epoxy group;
R , R , R , R , are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -
3 4 5 6 a a a b a
CONR R , oxo, thio wherein R and R are independently of each other H or (C1-6)alkyl;
a b a b
R , R , R are independently of each other H, (C1-10)alkyl, wherein one or more non
7 8 9
neighbouring CH groups may be replaced with -O-, -S-, -CO-, -CO-O-, -O-CO-, –NR -, -CO-
NR -, –NR -CO-, -C=C-, or -C≡C-; wherein R is H or (C1-6)alkyl;
a a a
L is a linking group, such as straight-chain or branched C(1-12)alkyl, which is unsubstituted or
substituted by at least one CN, hal, OH, NR R , COOR , NO , and wherein one or more of the
a b a 2
non-adjacent CH groups may independently be replaced by a group selected from -O-, -CO-, -
CO-O-, -O-CO-, -NR -, -NR -CO-, -CO-NR -, -CH=CH-, -C≡C-, wherein R and R are
a a a a b
independently of each other H or C(1-6)alkyl,
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
m is 0 to 5.
It is understood, that (H) represents all hydrogen substituents on the indicated A-ring (i.e. on
C1, C2, C3, C4, C5 and C10). The skilled person will know how many H-substituents are
present for a specific substitution pattern of groups R , R , R , R on ring A. For example, m = 5
1 2 2’ 3
may represent a fully saturated ring having no double bonds, m = 3 may represent e.g. a ring
having one double bond (between e.g. C1-C2 or between C4-C5), m = 2 may represent e.g. a
ring having one double bond (between e.g. C1-C2 or between C4-C5) and R being oxo, and m =
0 may represent e.g. a fully unsaturated ring having double bonds between C1-C2 and between
C4-C5 and R being oxo. Thus the degree of unsaturation and nature of substituents determines
the number of H-atoms present or vice versa, the number of H-atoms is a way to indicate the
degree of unsaturation of ring A.
In specific embodiments, the compounds described herein according to formula I are based on a
polyhydroxylated cholane skeleton having a –L-X- substituent at C17, and wherein the hydroxyl
(or oxo-) substituents are preferably in two or more, preferably at least three, positions selected
from C1, C3, C6, C7, C12 (represented by groups R , R , R , R , R , respectively), more
1 3 4 5 6
preferably wherein the hydroxyl (or oxo-) substituents are at a total of three or four positions
selected from C1, C3, C6, C7, C12, most preferably wherein the hydroxyl (or oxo-) substituents
are at a total of three or four positions selected from C1, C3, C6, C7, C12 of which one hydroxyl
(or oxo-) substituent is in position C1 or C6.
Thus, in some embodiments, the compounds described herein have three hydroxyl (or oxo-
substituents) and the hydroxylation patterns include (i) a hydroxyl (or oxo-) substituent at C1 in
combination with following combinations of two further hydroxyl (or oxo-) substituents at
positions C3 and C7, C3 and C12, C7 and C12, and (ii) a hydroxyl (or oxo-) substituent at C6 in
combination with following combinations of two further hydroxyl (or oxo-) substituents at
positions C3 and C7, C3 and C12, and C7 and C12, and (iii) a hydroxyl (or oxo-) substituent at
both C1 and C6 in combination with a further hydroxyl (or oxo-) substituent at position C3 or C7
or C12.
In other embodiments, the compounds described herein have four hydroxyl (or oxo-) substituents
and the hydroxylation patterns include (i) a hydroxyl (or oxo-) substituent at C1 in combination
with three further hydroxyl (or oxo-) substituents at positions C3, C7 and C12; (ii) a hydroxyl (or
oxo-) substituent at C6 in combination with three further hydroxyl (or oxo-) substituents at
positions C3, C7 and C12 and (iii) a hydroxyl (or oxo-) substituent at positions C1 and C6 in
combination with following combinations of two further hydroxyl (or oxo-) substituents at
positions C3 and C7; C3 and C12; C7 and C12.
In a preferred embodiment, R , R , R are independently of each other H, (C1-10)alkyl, more
7 8 9
preferably methyl, ethyl, propyl, butyl, most preferably methyl.
In some embodiments, R , R are independently of each other H, hal, -OR , -COOR , wherein R
1 2 a a a
is H or (C1-6)alkyl, or form together with the C-atoms to which they are linked an epoxy group.
Preferably, R is H or hal, or forms together with R and the C-atoms to which R and R are
1 1 2
linked an epoxy group.
Preferably R is H or hal, more preferably H or Cl, Br, I.
Preferably, R , R , R , R are independently of each other H, -OR , -NR R , -COOR , -CONR R
3 4 5 6
a a b a a b
or oxo, wherein R and R are independently of each other H or (C1-6)alkyl.
More preferably R , is H, -OR , -NR R or oxo, wherein R and R are independently of each
3 a a b a b
other H or (C1-6)alkyl; R , R , R are independently of each other H, -OR or -NR R , wherein
4 5 6
a a b
R and R are independently of each other H or (C1-6)alkyl; and R , R , R are independently of
a b 7 8 9
each other H, (C1-10)alkyl, more preferably methyl, ethyl, propyl, butyl, most preferably methyl.
Thus, preferably, described are compounds of formula II and pharmaceutically acceptable salts
or stereoisomers thereof, preferably its stereoisomeric form IIa,
II IIa
wherein
R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
2 a a a b a a b
wherein R and R are independently of each other H or (C1-6)alkyl, or R , R form together
a b 1 2
with the C-atoms to which they are linked an epoxy group;
R , R , R , R , are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -
3 4 5 6
a a a b a
CONR R , oxo, thio wherein R and R are independently of each other H or (C1-6)alkyl;
a b a b
R is H or hal,
L is a linking group, such as straight-chain or branched C(1-12)alkyl, which is unsubstituted or
substituted by at least one CN, hal, OH, NR R , COOR , NO , and wherein one or more of the
a b a 2
non-adjacent CH groups may independently be replaced by a group selected from –O-, -CO-, -
CO-O-, -O-CO-, -NR -, -NR -CO-, -CO-NR -, -CH=CH-, -C≡C-, wherein R and R are
a a a a b
independently of each other H or C(1-6)alkyl,
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
m is 0 to 5.
In a preferred embodiment, at least three groups, preferably three or four groups, selected from
R , R , R , R and R are –OR or oxo, wherein R is H or C(1-6)alkyl.
1 3 4 5 6 a a
In another preferred embodiment, R and/or R are –OR or oxo.
1 4 a
More preferably, at least three groups, preferably three or four groups, selected from R , R , R ,
1 3 4
R and R are –OR or oxo, with the proviso that R and/or R are –OR or oxo, wherein R is H
6 a 1 4 a a
or C(1-6)alkyl.
In specific embodiments L (in all of the formulas disclosed herein) is a straight-chain or
branched C(1-12)alkyl, which is unsubstituted and wherein one or more of the non-adjacent CH
groups may independently be replaced by a group selected from –O-, -CO-, - CO-O-. Preferably
L is straight-chain or branched C(1-12)alkyl, more preferably a straight-chain or branched C(1-
6)alkyl as defined herein.
Preferably, X (in all of the formulas disclosed herein) is H, -OR , –COOR , -CONR R , wherein
a c a c
R is H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl. Preferably, R is -H, -(C1-6)alkyl, -NH-
CH -CO R or -NH-(CH ) -SO R , wherein R is -H or -(C1-6)alkyl.
2 2 a 2 2 3 a a
In preferred embodiments, group -L-X (in all of the formulas disclosed herein) is –(C1-6)alkyl-
COOR , more preferably –(CH ) -COOR , wherein R is -H or -(C1-6)alkyl.
a 2 2 a
Preferably, R is H or hal, or forms together with R and the C-atoms to which R and R are
2 1 1 2
linked an epoxy group.
In specific embodiments, R , R are -OR , thus specifically described are compounds of formula
IIIa, and all pharmaceutically acceptable salts or stereoisomers thereof, preferably its
stereoisomeric form IIIb
a L X
m R R
IIIa IIIb
wherein
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H, -OR , -NR R , wherein R
1 a a a b a a b a a b a
and R are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-
atoms to which R , R are linked to an epoxy group;
R2 is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H or hal, wherein R and R
a a a b a a b a b
are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-atoms
to which R , R are linked to an epoxy group;
R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo,
a a a b a a b
thio, preferably H, oxo, -OR , -NR R , wherein R and R are independently of each other H or
a a b a b
(C1-6)alkyl;
R is H or hal,
L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one or more
of the non-adjacent CH groups may independently be replaced by a group selected from –O-, -
CO-, - CO-O;
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
R is H or C(1-6)alkyl;
m is 0 to 5.
In other specific embodiments, R6 is -OR and R1 is either -OR or forms with R an epoxide,
a a 2
and thus specifically described are compounds of formula IIIc and IIId, and all pharmaceutically
acceptable salts or stereoisomers thereof, preferably its stereoisomeric forms IIIe /IIIe and
IIIf /IIIf
L X L X
OR OR
R R R R
4 R '
IIIc IIId
OR O
IIIe IIIf
IIIe IIIf
wherein
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H or hal, wherein R and R
2 a a a b a a b a b
are independently of each other H or (C1-6)alkyl;
R , R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R ,
3 4 5 a a a b a a b
oxo, thio, preferably H, oxo, -OR , -NR R , wherein R and R are independently of each other
a a b a b
H or (C1-6)alkyl;
R is H or hal,
L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one or more
of the non-adjacent CH groups may independently be replaced by a group selected from –O-, -
CO-, - CO-O;
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
R is H or C(1-6)alkyl,
m is 0 to 5.
In specific embodiments, R is -OR and R is either -OR or oxo, and thus specifically described
are compounds of formula IIIg and IIIh, and all pharmaceutically acceptable salts or
stereoisomers thereof, preferably its stereoisomeric forms IIIi , IIIi
R O R
IIIg IIIh
L X L X
OR OR
R O R R O R
a 5 a 5
(H) (H)
R ' R '
IIIi IIIi
wherein
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H, -OR , -NR R , wherein R
a a a b a a b a a b a
and R are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-
b 1 2
atoms to which R1, R2 are linked to an epoxy group;
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H or hal, wherein R and R
a a a b a a b a b
are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-atoms
to which R , R are linked to an epoxy group;
R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo,
4 5 a a a b a a b
thio, preferably H, oxo, -OR , -NR R , wherein R and R are independently of each other H or
a a b a b
(C1-6)alkyl;
R is H or hal,
L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one or more
of the non-adjacent CH groups may independently be replaced by a group selected from –O-, -
CO-, - CO-O;
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
R is H or C(1-6)alkyl,
m is 0 to 5.
In specific embodiments, R5, R6 are -OR , thus specifically described are compounds of formula
IIIj, and all pharmaceutically acceptable salts or stereoisomers thereof, preferably its
stereoisomeric form IIIk
OR L X
R OR
(H) R OR
m 3 a
4 (H)
IIIj IIIk
wherein
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H, -OR , -NR R , wherein R
1 a a a b a a b a a b a
and R are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-
atoms to which R , R are linked to an epoxy group;
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H or hal, wherein R and R
2 a a a b a a b a b
are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-atoms
to which R1, R2 are linked to an epoxy group;
R , R , are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo,
a a a b a a b
thio, preferably H, oxo, -OR , -NR R , wherein R and R are independently of each other H or
a a b a b
(C1-6)alkyl;
R is H or hal,
L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one or more
of the non-adjacent CH groups may independently be replaced by a group selected from –O-, -
CO-, - CO-O;
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl;
R is H or C(1-6)alkyl,
m is 0 to 5.
In specific embodiments, R is –OR in compound of formula IIIa (and stereoisomeric forms
thereof), or R is –OR in compounds of formula IIIc and IIId (and stereoisomeric forms
thereof), or both R and R , are -OR in compounds of formula IIIg, IIIh, and IIIk (and
stereoisomeric forms thereof), wherein R is H or (C1-6)alkyl.
Also described are compounds of formula IV (wherein R is oxo) and all pharmaceutically
acceptable salts or stereoisomers thereof,
O OR
wherein
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H, -OR , -NR R , wherein R
1 a a a b a a b a a b a
and R are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-
atoms to which R , R are linked to an epoxy group;
R is H or hal, or R forms together with R and the C-atoms to which R , R are linked to an
2 2 1 1 2
epoxy group;
R is H or hal,
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo, thio, preferably H, oxo, -OR , -
4 a a a b a a b a
NR R , wherein R and R are independently of each other H or (C1-6)alkyl,
a b a b
L is a straight-chain or branched C(1-12)alkyl;
X is H, -OR , –COOR , -CONR R , wherein R is H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -
a c a c a
NH-(CH ) -CO R or -NH-(CH ) -SO R , wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl,
2 n 2 a a
2 p 3 a
R is H or C(1-6)alkyl, and
m is 1, 2, 3 or 4.
Preferably, m is 4, if ring A is fully saturated, and m is 0 or 2, if ring A is partially (one double
bond) or fully (two double bonds) unsaturated.
In a preferred embodiment, R or R or both R and R in compound IV are -OR , wherein R is
1 4 1 4 a a
H or (C1-6)alkyl.
Also described are compounds of formula V (wherein R is –OR ) and all pharmaceutically
acceptable salts or stereoisomers thereof, preferably its stereoisomeric forms Va and Vb
R'O OR
L X L X
OR OR
R O OR R O OR
a a a a
(H) m
R ' R '
Va Vb
wherein
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , preferably H, -OR , -NR R , wherein R
a a a b a a b a a b a
and R are independently of each other H or (C1-6)alkyl, or R forms together with R and the C-
b 1 2
atoms to which R1, R2 are linked to an epoxy group;
R is H or hal, or R forms together with R and the C-atoms to which R , R are linked to an
2 2 1 1 2
epoxy group;
R is H or hal,
R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo, thio, preferably H, oxo, -OR , -
4 a a a b a a b a
NR R , wherein R and R are independently of each other H or (C1-6)alkyl,
a b a b
L is a straight-chain or branched C(1-12)alkyl;
X is H, -OR , –COOR , -CONR R , wherein R is H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -
a c a c a
NH-(CH ) -CO R or -NH-(CH ) -SO R , wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl,
2 n 2 a a
2 p 3 a
R is H or C(1-6)alkyl, and
m is 1, 2, 3, 4 or 5.
Preferably, m is 5, if ring A is fully saturated, and m is 1 or 3, if ring A is partially (one double
bond) or fully (two double bonds) unsaturated.
In a preferred embodiment, R or R or both R and R in any of compounds of formula V, Va,
1 4 1 4
and Vb are -OR , wherein R is H or (C1-6)alkyl.
Some preferred examples include e.g. compounds with R = –OR , R = R = R =H, and R is -
3 a 1 2 2’ 4
OR of formula VIa, and all pharmaceutically acceptable salts or stereoisomers thereof, which
includes the C3α- and C3β-stereoisomer (VIa , VIa ); or
compounds with R being –OR , R = R = R =H, and R is -OR , of formula VIb, and all
3 a 4 2' 2’ 1 a
pharmaceutically acceptable salts or stereoisomers thereof, which includes the C1α/C3α-,
C1α/C3β-, C1β/C3α-, C1β/C3β-stereoisomer (VIb , VIb , VIb , VIb ); or
1 2 3 4
compounds with R being –OR , R = R =H, and R and R are -OR , of formula VIc, which
3 a 2' 2’ 4 a
includes the C1α/C3α-, C1α/C3β-, C1β/C3α-, C1β/C3β-stereoisomer each of them with C6
either in α or in β-position.
R O OR
R O OR
R O OR
VIa VIa
R O OR
a OR
R O OR R O OR
VIb VIb
1 2
OR a
OR a
R O OR
R O OR a a
VIb VIb
3 4
R O OR
wherein L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one
or more of the non-adjacent CH groups may independently be replaced by a group selected
from –O-, -CO-, - CO-O-, preferably straight-chain or branched C(1-6)alkyl,
R is H or C(1-6)alkyl,
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl, preferably H, -OR , -COOR , -CONR R .
a a c a c
Other preferred examples include e.g. compounds with R = oxo, R = R = R =H, R is -OR
3 1 2 2’ 4 a
and ring A is partially unsaturated of formula VIIa, VIIb, and all pharmaceutically acceptable
salts or stereoisomers thereof, which includes the C6α- or C6β-stereoisomer;
compounds with R = oxo, R = R , and either R is -OR and R is H or R and R from an
1 2 1 2
3 4 2' a
epoxide, of formula VIIc, VIId, and all pharmaceutically acceptable salts or stereoisomers
thereof, which includes the C1α- or C1β-stereoisomer (of the epoxide or –OR ); and
compounds with R = oxo, R = H, both R and R are -OR or oxo, and ring A is saturated or
3 2' 1 4 a
partially unsaturated of formula VIIe, VIIf, and all pharmaceutically acceptable salts or
stereoisomers thereof, which includes the C1α/C6α-, C1α/C6β-, C1β/C6α-, C1β/C6β-
stereoisomer,
O OR
O OR
VIIa VIIb
O OR
O OR
VIIc VIId
a OR
O OR
a O OR
a OR
VIIe VIIf
wherein L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one
or more of the non-adjacent CH groups may independently be replaced by a group selected
from –O-, -CO-, - CO-O-, preferably straight-chain or branched C(1-6)alkyl,
R is H or C(1-6)alkyl,
X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each
a a a b c a c a b
other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R ,
c 2 n 2 a 2 p 3 a
wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl, preferably H, -OR , -COOR , -CONR R .
a a c a c
The term "alkyl" refers to a straight chain or branched carbon chain comprising the specified
number of carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-
butyl, 1-methylpropyl, 2-methylpropyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-
methylbutyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, n-hexyl, 1-
methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-
ethylbutyl, 1,1-dimethyl butyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-
dimethylbutyl, 3,3-dimethyl butyl, n-heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-
methylhexyl, 5-methylhexyl, 1-ethylpentyl, 2-ethylpentyl, 3-ethylpentyl, 4-ethylpentyl, 1-
propylbutyl, 2-propylbutyl, 3-propylbutyl, 1,1-dimethylpentyl, 1,2-dimethylpentyl, 1,3-
dimethylpentyl, 1,4-dimethylpentyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl. 2,4-dimethylpentyl,
3,3-dimethylpentyl, 3,4-dimethylpentyl, 4,4-dimethylpentyl, 1-methylethylbutyl, 1-methyl
ethylbutyl, 2-methylethylbutyl, 1-ethylmethylbutyl, 1-ethylmethylbutyl, 1,1-
diethylpropyl, n-octyl, n-nonyl, n-decyl and the like.
Thus the term "C(1-6)alkyl" as used herein refers to branched or straight alkyl groups and
includes "linear C(1-6)alkyl", such as methyl, ethyl, n-propyl, n-butyl, n-pentyl and n-hexyl, and
"branched C(3-6)alkyl", such as isopropyl, isobutyl, tert-butyl, 2-pentyl, 3-pentyl, 2-methylbutyl,
3-methylbutyl, 3-methylbutyl, 2,2-dimethyl-propyl, 2-hexyl, 3-hexyl, 3-methylpentyl, 3-
methylpentyl, 2,2-dimethyl-butyl, 3,3-dimethyl-butyl, 2,3-dimethylbutyl, 2,3-dimethyl
butyl and 3,3-dimethylbutyl.
The term "halogen" (or “hal”) includes fluoro, chloro, bromo and iodo, preferably chloro and
bromo, more preferably bromo.
The term "oxo" refers to an oxygen atom connected by a double bond (=O).
The term "thio" refers to a sulfur atom connected by a double bond (=S).
Index “m” is 1, 2, 3, 4, or 5.
It is understood that if one or more of the above defined terms occur more than once in a formula
(e.g. R , R , R ), each term is defined independently of the other.
a b c
The compounds described herein may contain one chiral plane, one or more asymmetric or chiral
centers and can exist in different stereoisomeric forms, such as racemates and racemic mixtures,
optically pure enantiomers, enantiomeric mixtures, optically pure diastereomers and
diastereomeric mixtures. All stereoisomeric forms of the intermediates and compounds described
herein as well as mixtures thereof, including racemic and diastereomeric mixtures, which possess
properties useful in the treatment of the conditions discussed herein, form a part of the present
disclosure.
The compounds described herein may be separated into their individual enantiomers and
diastereoisomers by standard techniques known in the art, such as e.g. fractional crystallization
from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof, or via chiral
chromatography using an optically active stationary phase. Absolute stereochemistry may be
determined by X-ray crystallography of crystalline products or crystalline intermediates which
are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute
configuration. Enantiomers and diastereomers may be separated by use of a chiral HPLC column
and by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an
appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's
acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual
diastereoisomers to the corresponding pure enantiomers. Alternatively, any stereoisomer of a
compound described herein may be obtained by stereospecific synthesis using optically pure
starting materials or reagents of known absolute configuration.
Such enenatiomeric or diastereomeric separation or stereospecific synthesis may be particularly
desirable if enantiomers or diastereomers differ in biological activity.
The present disclosure is meant to comprehend all such isomeric forms of the compounds of the
invention, including the E and Z geometric isomers of double bonds and mixtures thereof. A
number of the compounds described herein and intermediates therefore exhibit tautomerism and
therefore may exist in different tautomeric forms under certain conditions. The term "tautomer"
or "tautomeric form" refers to structural isomers of equal energies (in 50:50 mixtures) or
different energies which are interconvertible via a low energy barrier. For example, proton
tautomers include interconversions via migration of a proton, such as keto-enol and imine-
enamine isomerizations. Valence tautomers include interconversions by reorganization of some
of the bonding electrons. All such tautomeric forms are within the scope of the disclosure. The
depiction of any particular tautomeric form in any of the structural formulas herein is not
intended to be limiting with respect to that form; but is meant to be representative of the entire
tautomeric set.
It is further understood that the compounds described herein include hydrates, solvates,
polymorphs, crystalline, hydrated crystalline and amorphous forms of the compounds described
herein, and pharmaceutically acceptable salts thereof.
For example, the compounds described herein and intermediates may exist in unsolvated as well
as solvated forms with solvents such as water, ethanol, isopropanol and the like, and both
solvated and unsolvated forms are included within the scope of the invention. Solvates for use in
the methods aspect of the invention should be with pharmaceutically acceptable solvents.
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically
acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic
acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric,
ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.
Particularly preferred are the ammonium, calcium, lithium, magnesium, potassium, and sodium
salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of
primary, secondary, and tertiary amines, substituted amines including naturally occurring
substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine,
caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-
dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine,
glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine,
morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, TEA,
trimethylamine, tripropylamine, tromethamine, and the like.
When the compound described herein is basic, salts may be prepared from pharmaceutically
acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic,
benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, formic, fumaric, gluconic,
glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic,
methanesulfonic, malonic, mucic, nitric, pamoic, pantothenic, phosphoric, propionic, succinic,
sulfuric, tartaric, p-toluenesulfonic acid, trifluoroacetic acid, and the like. Particularly preferred
are citric, fumaric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids. It
will be understood that, as used herein, references to the compounds described herein are meant
to also include the pharmaceutically acceptable salts, such as the hydrochloride salt.
Described herein are methods of production of the compounds described herein, which are able
to overcome the disadvantages (e.g. poor yields) associated with the known prior art method.
According to reported procedures a 1,3,7,12-tetrahydroxy compound is obtained by converting a
suitably protected C3-oxo-cholic acid derivative into the corresponding enone, subsequently
functionalizing the enone by nucleophilic epoxidation, followed by epoxide ring opening to give
(after suitable deprotection schemes) the desired 1,3,7,12-tetrahydroxy compound.
It was found that particularly suitable methods for introduction of the hydroxyl functionality (e.g.
at C1) include silicon based conjugate addition to a key intermediate enone and subsequent
oxidative removal of the silicon group (under Tamao-Fleming conditions as described in e.g.
Fleming, I. et al, J. Chem. Soc., Perkin Trans. 1, 1995, 317-337.), which enables obtaining the
final intermediates in high yields and stereoselectivity.
Alternatively, Applicants have found that under specific conditions introduction of the hydroxyl
functionality (e.g. at C1) may be achieved in good yields via epoxidation of the key intermediate
enone if said enone is protected as a branched alkyl ester, such as the isopropylester (without
significant hydrolysis of the ester functionality under basic conditions).
Furthermore, epoxide opening with lithium bromide alone or in combination with sodium
triacetoxyborohydride (in place of alternative reagents including selenides or samarium iodide)
gives the intermediate dibrominated ketone or alcohol respectively in high yields, which could be
debrominated to provide the final key compounds using non toxic and inexpensive reagents.
Additionally, it was found that the reduction of all the hydroxyketones used in the syntheses,
when performed with sodium triacetoxyborohydride afforded a single diasteroisomer (i.e. the
anti diol) in contrast to epimeric mixtures obtained by the use of sodiumborohydride or other
reducing agents.
The compounds described herein are useful as effective ligands or modulators of the ROR
receptor and in particular of the ROR gamma receptor. They are therefore useful for the
treatment and/or prevention of disorders responsive to the modulation of the ROR gamma
receptor, such as diabetes and diabetes-related disorders, and in particular type II diabetes.
Thus, also described is the use of at least one compound described herein as effective ligands or
modulators of the ROR receptor and in particular of the ROR gamma receptor.
Also described are use of at least one compound described herein for the treatment or prevention,
suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in
need thereof.
More specifically, also described is the use of a therapeutically effective amount of at least one
ROR gamma receptor ligand of formula I to VII, or a pharmaceutically acceptable salt or
stereoisomer thereof, for the treatment or prevention, or suppression of a disease mediated by the
ROR gamma receptor in a subject in need thereof, wherein the disease is selected from the group
consisting of diabetes and diabetes-related disorders, in particular type II diabetes.
More specifically, described is the use of a therapeutically effective amount of at least one
compound of formula I to VII, or a pharmaceutically acceptable salt or stereoisomer thereof, for
the treatment or prevention, or suppression of diabetes and/or diabetes-related disorders, in
particular type II diabetes.
In some embodiments the compounds described herein may be used singly, in other
embodiments, the compounds of the invention may be used in combination with other
compounds of the invention or in combination with other therapeutically active agents. Examples
of other therapeutically active ingredients (for combined administration with one ro more
compounds of the invention) that may be useful for the treatment and/or prevention and/or
amelioriation of the diseases or conditions for which the compounds described herein are useful,
i.e. diabetes and/or diabetes-related disorders, in particular type II diabetes, include, but are not
limited to anti-diabetic agents, lipid-lowering agents, anti-hypertensive agents, and anti-obesity
agents, such as the following:
(a) Anti-diabetic agents, for example, (1) glitazones (e.g., ciglitazone, darglitazone, englitazone,
isaglitazon, pioglitazone, rosiglitazone, troglitazone, tularik, BRL49653, CLX-0921, 5-BTZD),
and PPAR ligands such as GW-0207, LG-100641 and LY-300512; (2) biguanides such as
buformin, metformin and phenformin; (3) protein tyrosine phosphatase-1B (PTP-1B) inhibitors;
(4) sulfonylureas such as acetohexamide, chlorpropamide, diabinese, glibenclamide, glipizide,
glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide and
tolbutamide; (5) meglitinides such as repaglinide, nateglinide, and the like; (6) α-glucosidase
inhibitors such as acarbose, adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-
Q, salbostatin, CKD-711, MDL-25,637, MDL-73,945, and MOR14; (7) α-amylase inhibitors
such as tendamistat, trestatin, and Al-3688; (8) insulin secretagogues such as linogliride, A-4166
and the like; (9) fatty acid oxidation inhibitors such as clomoxir, and etomoxir; (10) α-2
antagonists such as midaglizole, isaglidole, deriglidole, idazoxan, earoxan, and fluparoxan; (11)
insulin and insulin mimetics such as biota, LP-100, novarapid, insulin detemir, insulin lispro,
insulin glargine, insulin zinc suspension (lente and ultralente), Lys-Pro insulin, GLP-1 (73-7)
(insulintropin), and GLP-1 (7-36)-NH ; (12) non-thiazolidinediones such as JT-501, farglitazar
(GW-2570/GI-262579), and muraglitazar; PPAR antagonists, such as muraglitazar, and the
compounds disclosed in US 6,414,002; (13) PPAR dual agonists such as MK-0767/KRP-297,
CLX-0940, GW-1536, GW-1929, GW-2433, L-796449, LR-90, and SB219994; (14) other
insulin sensitizers; (15) VPAC2 receptor agonists; (16) glucokinase activators; and (17) DPP-4
inhibitors, such as sitagliptin (Januvia ), isoleucine thiazolidide (P32/98); NVP-DPP-728;
vildagliptin (LAF 237); P93/01; denagliptin (GSK 823093), SYR322, RO 0730699, TA-6666,
and saxagliptin (BMS 477118).
(b) lipid lowering agents, for example, (1) bile acid sequestrants such as cholestyramine,
colesevelam, colestipol, dialkylaminoalkyl derivatives of a cross-linked dextran, Colestid(R),
LoCholest(R), and Questran(R), and the like; (2) HMG-CoA reductase inhibitors such as
atorvastatin, itavastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rivastatin, rosuvastatin,
and simvastatin, ZD-4522, and the like; (3) HMG-CoA synthase inhibitors; (4) cholesterol
absorption inhibitors such as stanol esters, beta -sitosterol, sterol glycosides such as tiqueside,
and azetidinones like ezetimibe; (5) acyl coenzyme A-cholesterol acyl-transferase (ACAT)
inhibitors such as avasimibe, eflucimibe, KY505, and SMP797, and the like; (6) CETP inhibitors
such as JTT705, torcetrapib, CP532632, BAY63-2149, SC591, and SC795, and the like; (7)
squalene synthase inhibitors; (8) antioxidants such as probucol; (9) PPAR-a agoists such as
beclofibrate, benzafibrate, ciprofibrate, clofibrate, etofibrate, fenofibrate, gemcabene,
gemfibrozil, and other fibric acid derivatives, e.g., GW7647, BM170744, LY518674,
Atromid(R), Lopid(R), and Tricor(R), and compounds described in WO 97/36579, and the like;
(10) FXR receptor modulators such as GW4064, SR103912, and the like; (11) LXR receptor
ligands such as GW3965, T9013137, and XTCO179628, and the like; (12) lipoprotein synthesis
inhibitors such as niacin; (13) renin/angiotensin system inhibitors; (14) PPAR-d partial agonists;
(15) bile acid reabsorption inhibitors such as BARI1453, SC435, PHA384640, S8921,
AZD7706, and the like; (16) PPAR-d agonists such as GW501516, GW590735, and compounds
described in WO97/28149, and the like; (17) triglyceride synthesis inhibitors, (18) microsomal
triglyceride transport (MTTP) inhibitors such as inplitapide, LAB687, and CP346086; (19)
transcription modulators, (20) squalene epoxidase inhibitors; (21) low-density lipoprotein (LDL)
receptor inducers; (22) platelet aggregation inhibitors; (23) 5-LO or FLAP inhibitors; and (24)
niacin receptor agonists; and
(c) anti-hypertensive agents, for example, (1) diuretics such as thiazides including
chlorthalidone, chlorothiazide, dichlorphenamide, hydroflumethiazide, indapamide and
hydrochlorothiazide; loop diuretics such as bumetanide, ethacrynic acid, furosemide, and
torsemide; potassium sparing agents such as amiloride, triamterene; aldosterone antagonists such
as spironolactone, and epirenone, and the like; (2) beta -adrenergic blockers such as acebutolol,
atenolol, betaxolol, bevantolol, bisoprolol, bopindolol, carteolol, carvedilol, celiprolol, esmolol,
indenolol, metaprolol, nadolol, nebivolol, penbutolol, pindolol, propanolol, sotalol, tertatolol,
tilisolol, and timolol, and the like; (3) calcium channel blockers such as amlodipine, aranidipine,
azelnidipine, barnidipine, benidipine, bepridil, cinaldipine, clevidipine, diltiazem, efonidipine,
felodipine, gallopamil, isradipine, lacidipine, lemildipine, lercanidipine, nicardipine, nifedipine,
nilvadipine, nimodipine, nisoldipine, nitrendipine, manidipine, pranidipine, and verapamil, and
the like; (4) angiotensin converting enzyme (ACE) inhibitors such as benazepril, captopril,
cilazapril, delapril, enalapril, fosinopril, imidapril, lisinopril, moexipril, quinapril, quinaprilat,
ramipril, perindopril, perindropril, quanipril, spirapril, tenocapril, trandolapril, and zofenopril,
and the like; (5) neutral endopeptidase inhibitors such as omapatrilat, cadoxatril, ecadotril,
fosidotril, sampatrilat, AVE7688, ER4030, and the like; (6) endothelin antagonists such as
bosentan, tezosentan, A308165, and YM62899, and the like; (7) vasodilators such as
hydralazine, clonidine, minoxidil, and nicotinyl alcohol; (8) angiotensin II receptor antagonists
such as candesartan, eprosartan, irbesartan, losartan, losartan and hydrochlorothiazide,
pratosartan, tasosartan, telmisartan, valsartan, EXP-3137, FI6828K, and RNH6270, and the like;
(9) a/ beta -adrenergic blockers such as nipradilol, arotinolol, and amosulalol; (10) a1 blockers
such as terazosin, urapidil, prazosin, bunazosin, trimazosin, doxazosin, naftopidil, indoramin,
WHIP164, and XEN010; (11) a2 agonists such as lofexidine, tiamenidine, moxonidine,
rilmenidine, and guanobenz; (12) aldosterone inhibitors; and
(d) anti-obesity agents, such as (1) growth hormone secretagogues, growth hormone
secretagogue receptor agonists/antagonists, such as NN703, hexarelin, MK-0677, SM-130686,
CP-424,391, L-692,429, and L-163,255; (2) protein tyrosine phosphatase-1B (PTP-1B)
inhibitors; (3) cannabinoid receptor ligands, such as cannabinoid CB receptor antagonists or
inverse agonists, such as rimonabant (Sanofi Synthelabo), AMT-251, and SR-14778 and SR
141716A (Sanofi Synthelabo), SLV-319 (Solvay), BAY 65-2520 (Bayer); (4) anti-obesity
serotonergic agents, such as fenfluramine, dexfenfluramine, phentermine, and sibutramine; (5)
beta 3-adrenoreceptor agonists, such as AD9677/TAK677 (Dainippon/Takeda), CL-316,243, SB
418790, BRL-37344, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243,
Trecadrine, Zeneca D7114, SR 59119A; (6) pancreatic lipase inhibitors, such as orlistat
(Xenical(R)), Triton WR1339, RHC80267, lipstatin, tetrahydrolipstatin, teasaponin,
diethylumbelliferyl phosphate; (7) neuropeptide Y1 antagonists, such as BIBP3226, J-115814,
BIBO 3304, LY-357897, CP-671906, GI-264879A; (8) neuropeptide Y5 antagonists, such as
GW-569180A, GW-594884A, GW-587081X, GW-548118X, FR226928, FR 240662,
FR252384, 1229U91, GI-264879A, CGP71683A, LY-377897, PD-160170, SR-120562A, SR-
120819A and JCF-104; (9) melanin-concentrating hormone (MCH) receptor antagonists, such as
those disclosed in WO 01/21577 and WO 01/21169; (10) melanin-concentrating hormone 1
receptor (MCH1R) antagonists, such as T-226296 (Takeda); (11) melanin-concentrating
hormone 2 receptor (MCH2R) agonist/antagonists; (12) orexin-1 receptor antagonists, such as
SBA, and those disclosed in WO 01/96302, WO 01/68609, WO 02/51232, and WO
02/51838; (13) serotonin reuptake inhibitors such as fluoxetine, paroxetine, and sertraline; (14)
melanocortin agonists, such as Melanotan II, CHIR86036 (Chiron), ME-10142, and ME-10145
(Melacure), CHIR86036 (Chiron); PT-141, and PT-14 (Palatin); (15) other MC4R (melanocortin
4 receptor) agonists; (16) 5HT-2 agonists; (17) 5HT2C (serotonin receptor 2C) agonists, such as
BVT933, DPCA37215, WAY161503, R-1065; (18) galanin antagonists; (19) CCK agonists; (20)
CCK-1 agonists (cholecystokinin-A) agonists, such as AR-R 15849, GI 181771, JMV-180, A-
71378, A-71623 and SR146131; (21) GLP-1 agonists; (22) corticotropin-releasing hormone
agonists; (23) histamine receptor -3 (H3) modulators; (24) histamine receptor -3 (H3)
antagonists/inverse agonists, such as hioperamide, 3-(1H-imidazolyl)propyl N-(4-
pentenyl)carbamate, clobenpropit, iodophenpropit, imoproxifan, GT2394 (Gliatech), and O-[3-
(1H-imidazolyl)propanol]-carbamates (Kiec-Kononowicz, K. et al., Pharmazie, 55:349-55
(2000)), piperidine-containing histamine H3-receptor antagonists (Lazewska, D. et al.,
Pharmazie, 56:927-32 (2001), benzophenone derivatives and related compounds (Sasse, A. et al.,
Arch. Pharm.(Weinheim) 334:45-52 (2001)), substituted N-phenylcarbamates (Reidemeister, S.
et al., Pharmazie, 55:83-6 (2000)), and proxifan derivatives (Sasse, A. et al., J. Med. Chem.
43:3335-43 (2000)); (25) beta-hydroxy steroid dehydrogenase-1 inhibitors (beta -HSD-1); 26)
PDE (phosphodiesterase) inhibitors, such as theophylline, pentoxifylline, zaprinast, sildenafil,
amrinone, milrinone, cilostamide, rolipram, and cilomilast; (27) phosphodiesterase-3B (PDE3B)
inhibitors; (28) NE (norepinephrine) transport inhibitors, such as GW 320659, despiramine,
talsupram, and nomifensine; (29) ghrelin receptor antagonists; (30) leptin, including recombinant
human leptin (PEG-OB, Hoffman La Roche) and recombinant methionyl human leptin (Amgen);
(31) leptin derivatives; (32) other BRS3 (bombesin receptor subtype 3) agonists such as [D-
Phe6,beta-Ala11,Phe13,Nle14]Bn(6-14) and [D-Phe6,Phe13]Bn(6-13)propylamide; (33) CNTF
(Ciliary neurotrophic factors), such as GI-181771 (Glaxo-SmithKline), SR146131 (Sanofi
Synthelabo), butabindide, PD170,292, and PD 149164 (Pfizer); (34) CNTF derivatives, such as
axokine (Regeneron); (35) monoamine reuptake inhibitors, such as sibutramine; (36) UCP-1
(uncoupling protein-1), 2, or 3 activators, such as phytanic acid, 4-[(E)(5,6,7,8-tetrahydro-
,5,8,8-tetramethylnapthalenyl)propenyl]benzoic acid (TTNPB), retinoic acid; (37) thyroid
hormone beta agonists, such as KB-2611 (KaroBioBMS); (38) FAS (fatty acid synthase)
inhibitors, such as Cerulenin and C75; (39) DGAT1 (diacylglycerol acyltransferase 1) inhibitors;
(40) DGAT2 (diacylglycerol acyltransferase 2) inhibitors; (41) ACC2 (acetyl-CoA carboxylase-
2) inhibitors; (42) glucocorticoid antagonists; (43) acyl-estrogens; (44) dipeptidyl peptidase IV
(DP-IV) inhibitors, such as isoleucine thiazolidide, valine pyrrolidide, NVP-DPP728, LAF237,
P93/01, TSL 225, TMC-2A/2B/2C, FE 999011, P9310/K364, VIP 0177, SDZ 274-444 and
sitagliptin; (46) dicarboxylate transporter inhibitors; (47) glucose transporter inhibitors; (48)
phosphate transporter inhibitors; (49) Metformin (Glucophage(R)); and (50) Topiramate
(Topimax(R)); and (50) peptide YY, PYY 3-36, peptide YY analogs, derivatives, and fragments
such as BIM-43073D, BIM-43004C ( Olitvak, D.A. et al., Dig. Dis. Sci. 44(3):643-48 (1999 ));
(51) Neuropeptide Y2 (NPY2) receptor agonists such NPY3-36, N acetyl [Leu(28,31)] NPY 24-
36, TASP-V, and cyclo-(28/32)-Ac-[Lys28-Glu32]-(25-36)-pNPY; (52) Neuropeptide Y4
(NPY4) agonists such as pancreatic peptide (PP) as described in Batterham et al., J. Clin.
Endocrinol. Metab. 88:3989-3992 (2003 ), and other Y4 agonists such as 1229U91; (54) cyclo-
oxygenase-2 inhibitors such as etoricoxib, celecoxib, valdecoxib, parecoxib, lumiracoxib,
BMS347070, tiracoxib or JTE522, ABT963, CS502 and GW406381, and pharmaceutically
acceptable salts thereof; (55) Neuropeptide Y1 (NPY1) antagonists such as BIBP3226, J-115814,
BIBO 3304, LY-357897, CP-671906, GI-264879A; (56) Opioid antagonists such as nalmefene
(Revex (R)), 3-methoxynaltrexone, naloxone, naltrexone; (57) 11 beta HSD-1 (11-beta hydroxy
steroid dehydrogenase type 1) inhibitors such as BVT 3498, BVT 2733; and other compounds
such as aminorex; amphechloral; amphetamine; benzphetamine; chlorphentermine; clobenzorex;
cloforex; clominorex; clortermine; cyclexedrine; dextroamphetamine; diphemethoxidine, N-
ethylamphetamine; fenbutrazate; fenisorex; fenproporex; fludorex; fluminorex;
furfurylmethylamphetamine; levamfetamine; levophacetoperane; mefenorex; metamfepramone;
methamphetamine; norpseudoephedrine; pentorex; phendimetrazine; phenmetrazine; picilorex;
phytopharm 57; zonisamide, neuromedin U and analogs or derivatives thereof, oxyntomodulin
and analogs or derivatives thereof, Neurokinin-1 receptor antagonists (NK-1 antagonists); and
Qnexa.
The compounds described herein may be used in form of a pharmaceutical composition. Thus, in
another aspect, described is a pharmaceutical composition comprising at least one compound
described herein (or a pharmaceutically acceptable salt thereof) and a pharmaceutically
acceptable carrier and optionally at least one further therapeutically active agent as defined
above. The term "pharmaceutically acceptable salts" refers to salts prepared from
pharmaceutically acceptable non-toxic bases or acids including inorganic bases or acids and
organic bases or acids as defined hereinabove.
Conveniently, the compounds described herein may be combined in intimate admixture with a
pharmaceutical carrier according to conventional pharmaceutical techniques. The carrier may
take a wide variety of forms depending on the form of preparation desired for administration (as
defined hereinafter).
The compounds described herein are ROR (gamma) receptor ligands and have been shown to be
useful in the treatment, control or prevention of diseases, disorders or conditions responsive to
the modulation of the ROR (gamma) receptor, e.g. diabetes and diabetes-related disorders, in
particular type II diabetes.
Also described is a method for the treatment or prevention of disorders, diseases or conditions
responsive to the modulation of the ROR gamma receptor in a subject in need thereof, which
comprises administering to the subject a therapeutically or prophylactically effective amount of
at least one compound described herein, or a pharmaceutically acceptable salt thereof, optionally
in combination with at least one further therapeutically active agent as defined above.
Also described is a method for the treatment or prevention of diabetes and diabetes-related
disorders in a subject in need thereof which comprises administering to said subject a
therapeutically or prophylactically effective amount of at least one ROR gamma receptor ligand
described herein, optionally in combination with at least one further therapeutically active agent
as defined above.
Also described is a method for the treatment or prevention of type II diabetes in a subject in need
thereof which comprises administering to the subject a therapeutically or prophylactically
effective amount of at least one compound described herein, or a pharmaceutically acceptable
salt thereof, optionally in combination with at least one further therapeutically active agent as
defined above.
The terms "administration of" or "administering" a compound described herein should be
understood to mean providing a compound described herein (or a prodrug of a compound of the
invention) or a pharmaceutical composition thereof to a subject in need of treatment. The
administration of the compounds described herein in order to practice the present methods of
therapy is carried out by administering a therapeutically or prophylactically effective amount of
the compound (or composition) described herein and optionally a therapeutically effective
amount of at least one further therapeutically active compound to a subject in need of such
treatment or prophylaxis.
The term "therapeutically effective amount" as used herein means the amount of a compound
described herein that will elicit the desired biological or medical response in a tissue, system, or
subject, which includes alleviation of the symptoms of the disorder being treated. The term
"prophylactically effective amount" as used herein means the amount of a compound described
herein will elicit the desired biological or medical response in a tissue, system, or subject to
prevent the onset of the disorder in subjects as risk for the disorder. The therapeutically or
prophylactically effective amount, or dosage, of a specific compound described herein is
determined by the physician, but depends on factors such as the exact disease to be treated, the
severity of the disease and other diseases or conditions from which the patient suffers, the chosen
route of administration, other drugs and treatments which the patient may concomitantly require,
the patients age and constitution and other factors in the physician's judgement.
Any suitable route of administration may be employed for providing a subject, especially a
human with a therapeutically effective dosage of a compound described herein. For example,
oral, rectal, topical, parenteral (e.g. subcutaneous or intravenous infusion, and subcutaneous or
intravenous injection), ocular, pulmonary, nasal, and the like may be employed. Dosage forms
include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments,
aerosols, and the like. Preferably compounds of the invention are administered orally or
parenterally.
The effective dosage of active ingredient employed may vary depending on the particular
compound of choice, the mode of administration, the condition being treated and the severity of
the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
Typically a compound described herein (or combinations thereof) are administered at a daily
dosage of from about 0.001 mg to about 50 mgs per kilogram of subject body weight, preferably
given in a single dose or in divided doses two to six times a day, or in sustained release form. For
example, in the case of a 70 kg adult human, the total daily dose will generally be from about
0.07 mgs to about 3500 mgs. This dosage regimen may be adjusted to provide the optimal
therapeutic response. In case of oral administration, a suitable dosage range is, e.g. from about
0.01 mg to about 1500 mg of one or more compounds described herein per day, preferably from
about 0.1 mg to about 600 mg per day, more preferably from about 0.1 mg to about 100 mg per
day. For oral administration, the compositions are preferably provided in the form of tablets
containing from 0.01 to 1,000 mg, preferably 0.01, 0.05, 0.1, 0.5, 1, 2.5, 5, 10, 15, 20, 25, 30, 40,
50, 100, 250, 500, 600, 750, 1000, 1250 or 1500 mgs of the active ingredient for the
symptomatic adjustment of the dosage to the patient to be treated. In case of intranasal
administration, a suitable dosage range is e.g. a formulation comprising 0.001-10 percent by
weight solutions or suspensions of one or more compounds described herein may be used. In
case of intravenous administration, a suitable dosage range is from about 0.001 mg to about 50
mg, preferably from 0.01 mg to about 50 mg, more preferably 0.1 mg to 10 mg, of one or more
compounds of the invention per kg of body weight per day.
The above dosage regimen may be adjusted to provide the optimal therapeutic response. It may
be necessary to use dosages outside these limits in some cases. The exact amount of prophylactic
or therapeutic dosage of one or more compounds described herein will, of course, vary
depending on the particular compound or compounds of choice, the mode of administration, the
condition being treated and the severity of the condition being treated. It will also vary according
to the age, weight and response of the individual patient. Such dosage may be ascertained readily
by a person skilled in the art.
Also contemplated is the use of compounds described herein in combination with at least one
further therapeutically active compound. Such further therapeutically active compound may be
administered, by a route and in an amount commonly used therefore, and may be administered
separately or combined (in single or separate pharmaceutical compositions), simultaneously or
sequentially with one or more compounds described herein. In case of simultaneous use, a
pharmaceutical composition comprising both the at least one compound described herein and the
at least one additional therapeutically active agent may be used. Also described is the
administration of a single pharmaceutical dosage formulation comprising at least one ROR
gamma receptor ligand in combination with at least one further therapeutically active agent, as
well as administration of each active agent in its own separate pharmaceutical dosage
formulation. Where separate dosage formulations are used, the individual components of the
composition can be administered at essentially the same time, i.e., concurrently, or sequentially,
i.e. prior to or subsequent to the administration of the other component of the composition. It is
understood that the present disclosure includes all such regimes of simultaneous or sequential
treatment, and the terms "administration" and "administering" are to be interpreted accordingly.
Various organic or inorganic carrier materials conventionally used as materials for
pharmaceutical preparations may be used as pharmaceutically acceptable carrier for the
compounds described herein and the route of administration chosen. They are blended as
excipient, lubricant, binder or disintegrant for solid preparations; and solvent, solubilizing agent,
suspending agent, isotonicity agent, buffer, soothing agent and the like for liquid preparations.
Where necessary, an additive for pharmaceutical preparations such as preservative, antioxidant,
colorant, sweetening agent and the like can be used.
Typical examples of an excipient include lactose, sucrose, D-mannitol, D-sorbitol, starch,
pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose,
sodium carboxymethylcellulose, gum arabic, pullulan, light anhydrous silicic acid, synthetic
aluminum silicate, magnesium aluminate metasilicate and the like. Typical examples of a
lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like. Typical
examples of a binder include pregelatinized starch, saccharose, gelatin, gum arabic,
methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose,
sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropylcellulose, hydroxypropyl
methylcellulose, polyvinylpyrrolidone and the like. Typical examples of a disintegrant include
lactose, sucrose, starch, carboxymethylcellulose, calcium carboxymethylcellulose, sodium
croscarmellose, sodium carboxymethyl starch, light anhydrous silicic acid, low-substituted
hydroxypropylcellulose and the like. Typical examples of a solvent include water for injection,
physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame
oil, corn oil, olive oil, cottonseed oil and the like. Typical examples of a solubilizing agent
include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol,
trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium
salicylate, sodium acetate and the like. Typical examples of a suspending agent include
surfactants such as stearyltriethanolamine, sodium lauryl sulfate, lauryl aminopropionate,
lecithin, benzalkonium chloride, benzethonium chloride, glycerol monostearate and the like;
hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium
carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose,
hydroxypropylcellulose and the like; polysorbates, polyoxyethylene hydrogenated castor oil; and
the like. Typical examples of an isotonicity agent include sodium chloride, glycerol, D-mannitol,
D-sorbitol, glucose and the like. Typical examples of a buffer include phosphate buffer, acetate
buffer, carbonate buffer, citrate buffer and the like. Typical examples of a soothing agent include
benzyl alcohol and the like. Typical examples of a preservative include p-oxybenzoates,
chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
Typical examples of an antioxidant include sulfite, ascorbate and the like. Typical examples of a
colorant include aqueous edible tar pigments (e.g., foodcolors such as Food Color Red Nos. 2
and 3, Food Color Yellow Nos. 4 and 5, Food Color Blue Nos. 1 and 2 etc.), water insoluble lake
pigments (e.g., aluminum salt of the aforementioned aqueous edible tar pigment), natural
pigments (e.g., beta carotene, chlorophyll, red iron oxide and yellow ferric oxide) and the like.
Typical examples of a sweetening agent include saccharin sodium, dipotassium glycyrrhizinate,
aspartame, stevia and the like.
Examples of a suitable dosage form for a compound described herein include oral preparations
such as tablet (including sugar-coated tablet, film-coated tablet, sublingual tablet, orally
disintegrating tablet), capsule (including soft capsule, microcapsule), granule, powder, troche,
syrup, emulsion, suspension, film (e.g., mouth cavity disintegrating film) and the like; or
parenteral preparations such as injections (e.g., subcutaneous injections, intravenous injections,
intramuscular injections and intraperitoneal injections), external agents (e.g., preparations for
nasal administration, transdermal preparations and ointments), suppositories (e.g., rectal
suppositories and vaginal suppositories), pellets, drops, eye drops, pulmonary preparations
(inhalations) and the like. In addition, these preparations may be sustained-release preparations
(e.g., sustained-release microcapsule), such as an immediate release preparation or a sustained-
release preparation.
The pharmaceutical compositions described herein may be produced according to a method
conventionally used in the field of pharmaceutical preparations. The content of the at least one
compound described herein in a pharmaceutical composition varies depending on the nature of
the compound, the route of administration (and thus the nature of the pharmaceutical
preparation), etc., and is e.g. from 1 to 90 wt %, preferably from 5 to 80 wt %.
Also described is a kit providing a pharmaceutical composition described herein comprising at
least one compound described herein and optionally at least one further therapeutically active
compound. In one embodiment, the kit, described herein, may comprise a single oral dosage
formulation comprising both at least one ROR (gamma) receptor ligand and at least one further
therapeutically active ingredient in one compartment of the kit. In another embodiment, the kit,
described herein, may comprise at least two separate pharmaceutical compositions in separate
compartments, which are a first unit dosage form comprising a prophylactically or
therapeutically effective amount of at least one ROR (gamma) receptor ligand, or a
pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier or
diluents in a first compartment, and a second unit dosage form comprising a prophylactically or
therapeutically effective amount of at least one further active ingredient, or a pharmaceutically
acceptable salt or ester thereof, and a pharmaceutically acceptable carrier or diluent in a second
compartment.
The present invention is further exemplified by the following specific examples, which are
intended to illustrate the invention and are not to be construed as limiting the scope of the
invention in any manner. It is understood that a skilled person in the art can readily prepare
additional compounds of the present invention based on the procedures described herein. Those
skilled in the art will readily understand that known variations of the conditions and processes of
the following preparative procedures can be used to prepare these compounds.
Examples
Materials and Methods
All chemicals and solvents were purchased from ABCR, Acros, Aldrich, J.T. Baker, Fluka,
Merck, TCI, or Lancaster and used as such with the following exceptions: THF and DMF were
dried by passage over two 4” × 36” columns of anhydrous neutral A-2 alumina (Macherey und
Nagel; activated over night at 300 °C under a flow of N ) under an atmosphere of argon (H O
content < 30 ppm, Karl-Fischer titration). All temperatures are degrees Celsius unless otherwise
noted. All non-aqueous reactions were performed in flame dried glassware under an atmosphere
of argon / nitrogen unless stated otherwise. TLC was performed on Merck silica gel 60 F254
TLC aluminum plates and visualized with UV fluorescence quenching and p-Anysaldehyde-
stain. Concentrations under reduced pressure were performed by rotary evaporation at 37 °C at
the appropriated pressure, unless otherwise noted. Column chromatographic purification was
performed as flash chromatography with 0.3-0.5 bar pressure on silica gel (60 Å, 40-64 µm).
Distilled technical grade solvents were employed. The yields given refer to the purified products.
Uncorrected melting points were measured on a Büchi B-540 melting point apparatus using open
glass capillaries. NMR data was recorded on a VARIAN Mercury 300 MHz, Gemini 300 MHz,
Bruker ARX 300, Bruker AV 400, Bruker DRX 400 spectrometer. Measurements were carried
out at RT (ca. 22 °C) unless otherwise noted. Chemical shifts are given in ppm with the residual
solvent signal as internal standard [d]-chloroform at 7.26 and 77.00 ppm, d -DMSO at 2.50 and
1 13
39.52 ppm, [d]-methanol at 3.31 and 49.00 ppm, for H- and C, respectively. Multiplicities are
abbreviated as follows: singlet (s), doublet (d), triplet (t), apparent triplet (at), doublet-doublet
(dd), triplet-doublet (td), doublet-doublet-doublet (ddd), and multiplet (m), coupling constant(s)
are given in Hz. C-NMR spectra were recorded with 1H-decoupling. Infrared spectra were
recorded on a Perkin Elmer RXI FT-IR Spectrophotometer as thin films, absorptions are given in
wavenumbers (cm ). Mass spectrometric analyses were performed by the mass spectrometry
service of the Laboratorium für Organische Chemie at ETH Zürich by L. Bertschi and O. Greter
under direction of Dr. Zhang. ESI and HRMS measurements were carried out on a Bruker
Daltonics maxis and Varian IonSpec ESI FT-ICR at 4.7 Tesla. EI measurements were carried out
on a Waters Micromass AutoSpec Ultima at 70 eV.
The use of protecting groups for the amine and carboxylic acid functionalities to facilitate the
desired reaction and minimize undesired reactions is well documented. Conditions required to
remove protecting groups are found in standard textbooks such as Greene, T, and Wuts, P. G.
M., Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., New York, NY, 1991.
CBZ and BOC are commonly used protecting groups in organic synthesis, and their removal
conditions are known to those skilled in the art. For example, CBZ may be removed by catalytic
hydrogenation in the presence of a noble metal or its oxide such as palladium on activated carbon
in a protic solvent such as methanol or ethanol. In cases where catalytic hydrogenation is
contraindicated due to the presence of other potentially reactive functionalities, removal of CBZ
groups can also be achieved by treatment with a solution of hydrogen bromide in acetic acid or
by treatment with a mixture of TFA and dimethylsulfide. Removal of BOC protecting groups is
carried out with a strong acid, such as trifluoroacetic acid, hydrochloric acid, or hydrogen
chloride gas, in a solvent such as methylene chloride, methanol, or ethyl acetate.
Luciferase activity assay. Typically, 3T3L1 cells were grown to 60-70% confluence in a 24well
dish and transfected with the reporter genes (pMMP3-pGL3) (0.05 µg), pCMV-Renilla as
internal reference (0.05 µg) and the expression vectors for RORgamma (0.1 µg) by use of the
transfection reagent Fugene according to manufacture’s protocol (Invitrogen). Cells were grown
for an additional 48h after transfection. Luciferase activity was measured using the Luciferase
Detection System following manufacture’s protocol (Promega).
Insulin tolerance test. Typically, C57B6 mice (age 6 weeks) were fed a high fat diet (60%
calories derived from fat, Kliba) supplemented with 1β,3α,7α,12α-tetrahydroxy-5β-cholan
oate (or tetraol compound) at 0.1 % or 0.01 % or cholic acid (or CA) at 0.1 % and 0.01 %. High
fat diet feeding alone served as a control. After 6 weeks mice were tested for insulin sensitivity
by injection of 0.5 U/kg insulin, i.p. Blood glucose concentrations were measured before
injection and at 30, 60, 90 and 120 min post injection. Relative drop in blood glucose was
calculated for each mouse by dividing the time point value by the starting blood glucose value.
Therapeutic efficacy Typically, C57B6 mice (age 6 weeks) were fed a high fat diet (60%
calories derived from fat, Kliba) for 6 week to induce obesity related insulin resistance.
Subsequently the mice were divided in three groups: the first one was continued on high fat diet
supplemented with 0.01% tetraol compound, the second one on high fat diet supplemented with
0.01% cholic acid and the last one on high fat diet as a control. After 6 and 12 weeks on the
respective diets, blood glucose was measured using an Contour glucose monitor (Bayer AG,
Diabetes Care, Switzerland) and circulating insulin concentrations were determined using the
rat/mouse insulin assay supplied by Meso Scale Discovery (Gaithersburg, Maryland, USA).
Example 1: Synthesis of methyl-1β,3α,7α,12α-tetrahydroxy-5β-cholanoate.
(a) Methyl 3-oxo,7α,12α-dihydroxy-5β-cholanoate.
Cholic acid (50 g, 0.12 mol) was converted into the corresponding methylester (51g, 98%)
according to literature procedures (Rohacova J., et al. Org. Biomol. Chem., 2009, 7, 4973-4980;
Tohma M. et al., Chem. Pharm. Bull. 1986, 34 (7), 2890-2899). To a solution of the obtained
methylester (23 g, 59 mmol) in toluene (400 mL), Ag CO /Celite (40 g) was added. The
mixture was heated at 150 °C under vigorous stirring until TLC showed complete conversion of
the starting material (Rf = 0.27, AcOEt 100%) into a single less polar product (Rf = 0.58, AcOEt
100%). After 9h, the mixture was allowed to cool down to r.t. and the solid precipitates were
removed by filtration through a pad of Celite . The solvent was removed under reduced pressure
to give the crude material, which was triturated with Et O to give the corresponding ketone-
diol(19.7 g, 87%) as a white solid. Analytical data were in full agreement with the reported
values (Rohacova J., et al. Org. Biomol. Chem., 2009, 7, 4973-4980; Tohma M. et al., Chem.
Pharm. Bull. 1986, 34 (7), 2890-2899).
(b) Methyl 3-oxo,7α,12α-diacetoxy-5β-cholanoate.
To a solution of ketone-diol of step (a) (13 g, 31 mmol) in a mixture of acetic anhydride and
pyridine (50% vol, 100 mL), DMAP (380 mg, 3.1 mmol) was added. The reaction mixture was
stirred for for 1h at r.t., cooled at 0°C and quenched by adding MeOH dropwise. The solvents
were concentrated under reduced pressure and the residue was dissolved in EtOAc and washed
with 1M HCl and NaHCO . The organic phase was concentrated under reduced pressure to
3 (aq.)
give a solid residue, which was recrystallized from EtOAc/hexanes to afford bis acetoxy sterol
(14.8 g, 95%), whose analytical data were in full agreement with the reported values (Tohma M.
et al., Chem. Pharm. Bull. 1986, 34 (7), 2890-2899).
(c) Methyl 7α,12α-diacetoxy-2β,4β-dibromooxo-5β-cholanoate.
The bis acetoxy ketone of step (b) (11.47 g, 23 mmol) was dissolved in a mixture of CHCl (20
mL) and acetic acid (40 mL). A solution of Br (2.34 mL, 46 mmol) in acetic acid (24 mL) was
added dropwise. After 1h stirring at r.t., the mixture was quenched with NaHSO and
3(aq)
concentrated under reduced pressure to ¼ of its volume. The residue was dissolved in EtOAc and
washed with NaHCO (aq). The organic phase was concentrated under reduced pressure and the
residue was triturated with diisopropylether to afford 2,4-dibromo derivative (13.49 g, 90%) as
85 : 15 mixture of two major epimers, suitable however to be used as such in the next steps. An
aliquot of the crude was crystallized twice from CH2CL2/Et2O to give pure 2,4 dibromo
derivative (M.P. = 196 °C, Lit = 196-98 °C), whose analytical and spectroscopic data were
identical to the ones described (Tohma M. et al., Chem. Pharm. Bull. 1986, 34 (7), 2890-2899).
(d) Methyl 7α,12α-diacetoxyoxo-5β-cholenoate.
To a solution of the dibromoketone of step (c) (10.6 g, 16 mmol) in DMF (85 mL) were added
Li CO (1.9 g, 24 mmol) and LiBr (2.1 g, 24 mmol). After stirring at 80 °C under nitrogen for 8
h, TLC showed complete conversion of the starting material (Rf = 0.53, Hexanes/EtOAc 80 : 20)
into a single more polar spot (Rf = 0.35, Hexanes/EtOAc 80 : 20). The mixture was diluted with
EtOAc and washed with 1 M HCl. The organic phase was concentrated under reduced pressure
to give a crude residue which was triturated with diisopropylether to afford the intermediate
Methyl 7α,12α-diacetoxy-4β-bromooxo-5β-cholenoate as a white solid (8.6 g, 92%),
which was reacted in the next step without further purification.
To a solution of the previously obtained ∆Bromo-enone in acetic acid (80 mL), finely
divided Zn powder (4g, 63 mmol) was added. After stirring for 30 min. at r.t., complete
conversion of the starting material into a single spot was observed on TLC (Rf = 0.54,
Hexanes/EtOAc, 70 : 30). The solids were filtered through a pad of Celite and the resulting
solution was concentrated under reduced pressure to 1/5 of its volume. The residue was then
added into a flask containing 500 mL of ice-cold distilled water to give a solid precipitate, which
was filtered off and purified by flash chromatography (Hexanes/EtOAc, 70 : 30) to afford the
desired enone (5.6 g, 76 %), whose analytical data were in full agreement with the reported ones
(Tohma M. et al., Chem. Pharm. Bull. 1986, 34 (7), 2890-2899).
(e) Methyl 1β-dimethylphenylsilyl-7α,12α-diacetoxyoxo-5β-cholanoate.
Lithium metal (418 mg, 59.7 mmol) was suspended in THF (20 mL), cooled at 0 °C, and
Phenyldimethylchlorosilane (4.34 ml, 26.3 mmol) was added. Stirring was continued for 1h at
0°C, then the resulting red-purple solution was transferred via cannula to a suspension of CuI
(2.5 g, 13.1 mmol) in THF (20 mL), previously cooled at -30 °C. After 30 minutes, a solution of
Methyl 7α,12α-diacetoxyoxo-5β-cholenoate of step (d) (6 g, 11.9 mmol) in THF (20
mL) was added dropwise. After 30 minutes stirring at -30 °C, the reaction was quenched by
adding 0.1 M HCl and the mixture was extracted with Et O. Evaporation of the solvents under
reduced pressure afforded an oily residue, which was purified by flash chromatography to give
the silyl ketone. White solid: m. p. = 162 °C; = +44.9 (c = 1.00 in CHCl ); H NMR (400
[α ] 3
MHz, CDCl ): δ 7.47-7.43 (m, 2H), 7.36-7.32 (m, 3H), 5.12 (at, J = 2.7 Hz, 1H), 4.93 (dd, J =
.6, 3.4 Hz, 1H), 3.65 (s, 3H), 2.99 (dd, J = 15.6, 12.7 Hz, 1H), 2.44 (dd, J = 14.8, 7.5 Hz, 1H),
2.34 (ddd, J = 15.3, 10.0, 5.2 Hz, 1H), 2.32-2.15 (m, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 2.00-1.75
(m, 6H), 1.75-1.60 (m, 3H), 1.60-1.47 (m, 3H), 1.44-1.24 (m, 4H), 1.15-1.04 (m, 1H), 0.99 (s,
3H), 0.81 (d, J = 6.4 Hz, 3H), 0.71 (s, 3H), 0.38 (s, 3H), 0.33 (s, 3H); C NMR (101 MHz,
CDCl ): δ 212.2, 174.4, 170.5, 170.1, 139.3, 133.8, 133.8, 129.0, 127.9, 127.9, 75.2, 70.3, 51.5,
47.3, 45.0, 44.5, 43.5, 40.3, 38.4, 38.2, 37.5, 34.6, 32.3, 30.9, 30.7, 30.7, 30.5, 27.2, 25.8, 22.7,
22.1, 21.5, 21.3, 17.5, 12.2, -0.3, -0.4.; IR (film): ν = 2949, 2870, 1734, 1435, 1425, 1376, 1240,
-1 + +
1110, 1024 cm ; HRMS (ES ): m/z: Calcd for C H O NaSi (M + Na): 661.3531, found:
37 54 7
661.3525.
(f) Methyl 1β,3α-dihydroxy-7α,12α-diacetoxy-5β-cholanoate.
To a solution of the silyl-ketone of step (e) (2.5 g, 3.91 mmol) in a mixture of peracetic acid (20
mL, 40% in acetic acid) and acetic acid (10 mL), Hg(OAc) (1.5 g, 4.70 mmol) was added. The
mixture was stirred at r.t. for 6h, cooled at 0°C and carefully quenched by slow addition of
NaHSO (40% aq). The reaction mixture was concentrated under reduced pressure, diluted with
AcOEt and washed with NaHCO and brine. The solvents were evaporated under reduced
pressure to give the crude intermediate hydroxyketone as a major product (Rf = 0.29,
hexanes/EtOAc 4 : 3) which was reacted in the next step without purification.
The crude material was dissolved in a mixture of CH Cl /THF (1 : 2, 45 mL) and added to a
previously prepared solution of Na(OAc) BH at 0°C, obtained by adding NaBH (296 mg, 7.8
mmol) to a mixture of acetic acid/THF (1 : 1, 10 mL). After stirring at 0°C for 30 min., complete
conversion of the starting material into a major product (Rf = 0.25, EtOAc 100%) was observed,
without any detectable amount of the corresponding 3β epimer (Rf = 0.48, EtOAc 100%). The
solvents were evaporated under reduced pressure and the residue was dissolved in AcOEt and
washed with brine. Evaporation of the solvents under reduced pressure and purification of the
residue by flash chromatography (EtOAc/isopropanol 10 : 1) gave pure diol (860 mg, 42%),
whose analytical and spectroscopic data were in full agreement with the reported ones (Tohma
M. et al., Chem. Pharm. Bull. 1986, 34 (7), 2890-2899).
(g) Methyl-1β,3α,7α,12α-tetrahydroxy-5β-cholanoate.
Selective hydrolysis of the acetate groups using anhydrous base (such as sodium methoxide in
methanol) yields the tetrahydroxy-methylester. The identity of the compound was confirmed
through methylation of the corresponding free acid 1β,3α,7α,12α-tetrahydroxy-5β-cholanoic
acid. Free acid (7 mg, 0.016 mmol) was added to a mixture of MeOH (1 mL) containing acetyl
chloride (1 µL, 0.19 mmol). The mixture was stirred for 4h at r.t., the solvents were evaporated
to afford the desired methylester (5 mg, 69%). H NMR (300 MHz, CD OD): δ 3.93 (at, J = 2.8,
1H), 3.90-3.82 (m, 2H), 3.80 (dd, J = 5.0, 2.3 Hz, 1H), 3.65 (s, 3H), 2.45-2.28 (m, 4H), 2.01 (dd,
J = 12.0, 4.8 Hz, 1H), 1.92-1.48 (m, 12H), 1.47-1.24 (m,7H), 1.19-1.02 (m, 2H), 1.01 (s, 3H),
1.00 (d, J = 6.2 Hz, 3H), 0.72 (s, 3H).
Example 2: Synthesis of isopropyl-1β,3α,7α,12α-tetrahydroxy-5β-cholanoate.
(a) Methyl 3α,7α,12α-triacetoxy-5β-cholanoate.
Cholic acid (50 g, 0.12 mol) was converted into the corresponding methylester as reported in
Example 1(a). To a solution of the obtained methylester (30 g, 71 mmol) in a mixture of acetic
anhydride and pyridine (50% vol, 156 mL), DMAP (860 mg, 7.1 mmol) was added. The reaction
mixture was stirred for for 1h at r.t., cooled at 0°C, quenched by adding MeOH (60 mL)
dropwise and concentrated almost to dryness. The residue was dissolved in EtOAc and washed
with 1M HCl and NaHCO (aq.). The organic phase was concentrated under reduced pressure to
give the corresponding triacetoxy sterol (39 g, 100%), whose analytical properties were identical
a s reported in the literature (Opsenica D. et al, J. Med. Chem. 2000, 43, 3274-3282).
(b) Isopropyl 3α-hydroxy,7α,12α-diacetoxy-5β-cholanoate.
HO OAc
To a solution of the sterol of step (a) (29.5 g, 54 mmol) in isopropanol (150 mL) was added a
previously prepared solution of sodium isopropoxide, obtained by dissolving finely divided Na
(2.5 g, 108 mmol) in isopropanol (240 mL). The mixture was stirred at r.t. for 20 minutes, and
then quenched by adding KHSO4 (sat. aq.). The solvent was removed under reduced pressure to
give the crude material, which was re-dissolved in EtOAc and washed with brine. Evaporation of
the solvent and trituration of the crude residue with diisopropyl ether, gave the corresponding
alcohol (28.7 g, 100%). H NMR (400 MHz, CDCl ): δ 5.09-5.07 (m, 1H), 4.99 (sept., J = 6.3
Hz, 1H), 4.90 (dd, J = 5.5, 2.9 Hz, 1H), 3.54-3.45 (m, 1H), 2.29 (ddd, J = 15.6, 10.3, 5.1 Hz,
1H), 2.18 (dd, J = 9.4, 6.9 Hz, 1H), 2.12 (s, 3H), 2.08 (s, 3H), 2.07-1.81 (m, 7H), 1.81-1.49 (m,
8H), 1.49-1.24 (m, 6H), 1.22 (d, J = 6.3 Hz, 6H), 1.17-0.95 (m, 2H), 0.90 (s, 3H), 0.81 (d, J =
6.8 Hz, 3H), 0.72 (s, 3H).
(c) Isopropyl 3-oxo,7α,12α-diacetoxy-5β-cholanoate.
O OAc
To a solution of the alcohol of step (b) (28.7 g, 54 mmol) in acetic acid (550 mL), a solution of
NaClO (218 mL, 5% (aq), 268 mmol) was added dropwise. The reaction mixture was stirred for
1h at r.t., quenched with NaHSO (sat. aq), and the solvent was concentrated under reduced
pressure. The residue was dissolved in EtOAc and washed with NaHCO (aq.) and brine. The
solvent was evaporated under reduced pressure to give a solid residue, which was purified by
flash chromatography (Hexanes/EtOAc 4 : 3) to afford the desired ketone (21.6 g, 76%). H
NMR (400 MHz, CDCl ): δ 5.11 (at, J = 2.7 Hz, 1H), 5.04-4.95 (m, 2H), 2.98 (dd, J = 15.6,
13.9 Hz, 1H), 2.29 (ddd, J = 15.6, 6.9, 5.3 Hz, 1H), 2.23-2.07 (m, 6H), 2.11 (s, 3H), 2.06 (s, 3H),
1.99-1.74 (m, 5H), 1.74-1.57 (m, 4H), 1.49-1.24 (m, 6H), 1.22 (d, J = 6.3 Hz, 6H), 1.19-1.07
(m, 1H), 1.01 (s, 3H), 0.82 (d, J = 6.5 Hz, 3H), 0.76 (s, 3H).
(d) Isopropyl 7α,12α-diacetoxy-2β,4β-dibromooxo-5β-cholanoate.
O OAc
To the ketone of step (c) (10 g, 18.8 mmol) was dissolved in acetic acid (120 mL). A solution of
Br (1.93 mL, 37.5 mmol) in acetic acid (100 mL) was added dropwise. After 1h stirring at r.t.,
the mixture was poured into water. The solid precipitated was filtered, dried, and triturated with
diisopropyl ether to afford the 2,4-dibromo derivative (9.2 g, 71%). H NMR (400 MHz, CDCl3):
δ 5.35 (d, J = 11.9 Hz, 1H), 5.18 (at, J = 2.7 Hz, 1H), 5.06 (dd, J = 6.0, 3.1 Hz, 1H), 4.99 (sept.,
J = 6.3 Hz, 1H), 4.65 (dd, J = 14.2, 4.9 Hz, 1H), 2.62 (dd, J = 14.2, 5.5 Hz, 1H), 2.54 (dat, J =
.7, 2.0 Hz, 1H), 2.30 (ddd, J = 14.9, 9.4, 5.6 Hz, 1H), 2.21-2.10 (m, 2H), 2.13 (s, 3H), 2.12 (s,
3H), 2.04-1.81 (m, 4H), 1.80-1.62 (m, 6H), 1.50-1.24 (m, 4H), 1.21 (d, J = 5.7 Hz, 6H), 1.18-
1.12 (m, 1H), 1.01 (s, 3H), 0.82 (d, J = 6.4 Hz, 3H), 0.76 (s, 3H).
(e) Isopropyl 7α,12α-diacetoxy-4β-bromooxo-5β-cholenoate.
O OAc
To a solution of the dibromoketone of step (d) (9.2 g, 13.3 mmol) in DMF (60 mL) were added
Li CO (1.6 g, 20 mmol) and LiBr (1.7 g, 20 mmol). After stirring at 80 °C under nitrogen for 8
h, the mixture was poured into water and the solid precipitate was filtered, dried and triturated
with diisopropyl ether to afford the desired enone (6.8 g, 84%). H NMR (400 MHz, CDCl ): δ
6.77 (d, J = 10.3 Hz, 1H), 6.05 (d, J = 10.3 Hz, 1H), 5.34 (d, J = 13.4 Hz, 1H), 5.09-5.06 (m,
2H), 4.99 (sept., J = 6.2 Hz, 1H), 2.62 (dat, J = 16.0, 2.0 Hz, 1H), 2.29 (ddd, J = 15.3, 9.6, 5.7
Hz, 1H), 2.24-2.10 (m, 2H), 2.13 (s, 3H), 2.08 (s, 3H), 2.06-1.95 (m, 1H), 1.94-1.74 (m, 6H),
1.73-1.62 (m, 2H), 1.52-1.29 (m, 4H), 1, 26 (s, 3H), 1.22 (d, J = 6.1 Hz, 6H), 1.18-1.11 (m, 1H),
0.80 (d, J = 6.5 Hz, 3H), 0.78 (s, 3H).
(f) Isopropyl 1-epoxy-7α,12α-diacetoxy-4β-bromo-5β-cholanoate.
O OAc
To a solution of the bromo-enone of step (e) (6.8 g, 11.2 mmol) in Ethanol (450 mL) containing
DBU (1.83 mL, 12.3 mmol), urea-H O complex (2.6 g, 27.6 mmol) was added in three portions
over a period of 5h, while stirring at r.t. The mixture was quenched with NaHSO (aq.) and
KHSO (aq.) and the solvents were concentrated under reduced pressure. The residue was
dissolved in EtOAc and washed with 1M HCl and brine. Evaporation of the solvent under
reduced pressure and purification of the crude by flash chromatography (Hexanes/EtOAc 4: 2)
gave the desired epoxide (4.2 g, 60 %). H NMR (400 MHz, CDCl ): δ 5.09 (at, J = 2.9 Hz, 1H),
.06-5.04 (m, 1H), 4.99 (sept., J = 6.4 Hz, 1H), 4.74 (d, J = 11.1 Hz, 1H), 3.50 (d, J = 3.6 Hz,
1H), 3.42 (d, J = 3.6 Hz, 1H), 2.45-2.25 (m, 3H), 2.18 (dd, J = 9.2, 6.9 Hz, 1H), 2.11 (s, 3H),
2.10 (s, 3H), 1.94-1.61 (m, 8H), 1.49-1.35 (m, 3H), 1,34 (s, 3H), 1.3224 (m, 3H), 1.22 (d, J =
6.4 Hz, 6H), 0.80 (d, J = 6.5 Hz, 3H), 0.76 (s, 3H).
(g) Isopropyl 1β-hydroxy-2α,4β-dibromo-7α,12α-diacetoxyoxo-5β-cholanoate.
O OAc
To a solution of the epoxide of step (f) (300 mg, 0.48 mmol) in acetic acid (7 mL), LiBr (104
mg, 1.2 mmol) was added. After stirring at r.t. for 30 minutes the reaction mixture was poured
into water and the white precipitate was filtered and dried to give the corresponding
hydroxyketone (283 mg, 86%). H NMR (400 MHz, CDCl ): δ 5.68 (d, J = 13.3 Hz, 1H), 5.10
(at, J = 2.8 Hz, 1H), 5.05 (dd, J = 5.6, 2.7 Hz, 1H), 4.99 (sept., J = 6.0 Hz, 1H), 4.48 (d, J = 4.6
Hz, 1H), 4.13 (at, J = 4.5 Hz, 1H), 2.72 (td, J = 11.7, 3.9 Hz, 1H), 2.61 (dat, J = 15.6, 2.6 Hz,
1H), 2.45 (d, J = 4.0 Hz, 1H), 2.38 (ddd, J = 12.8, 5.2, 2.2 Hz, 1H), 2.29 (ddd, J = 15.2, 9.6, 5.2
Hz, 1H), 2.18 (dd, J = 9.2, 7.0 Hz, 1H), 2.16-2.09 (m, 2H), 2.15 (s, 3H), 2.03 (s, 3H), 1.95-1.66
(m, 6H), 1.51-1.25 (m, 4H), 1.22 (s, 3H), 1.22 (d, J = 6.4 Hz, 6H), 1.15 (m, 1H), 0.80 (d, J = 6.5
Hz, 3H), 0.78 (s, 3H).
(h) Isopropyl 1β,3α-dihydroxy-2α,4β-dibromo-7α,12α-diacetoxy-5β-cholanoate.
HO OAc
To a solution of the epoxide of step (f) (420 mg, 0.67 mmol) in acetic acid (10 mL), LiBr (117
mg, 1.3 mmol) was added. To the reaction mixture, a previously prepared solution of sodium
triacetoxyborohydride in acetic acid (obtained by adding 30.5 mg of NaBH to 2 mL of acetic
acid at 0°C), was added. After stirring at r.t. for 30 minutes the solvent was evaporated and the
residue was dissolved in EtOAc and washed with brine. Evaporation of the solvent and
trituration of the crude with diisopropyl ether gave the dibromo-diol derivative (402 mg, 85%).
H NMR (400 MHz, CDCl ): δ 5.04 (at, J = 2.4 Hz, 1H), 4.98 (sept., J = 6.5 Hz, 1H), 5.00-4.95
(m, 1H), 4.84 (at, J = 11.1 Hz, 1H), 4.56 (dd, J = 4.2, 3.1 Hz, 1H), 4.19 (br, 1H), 4.06 (dat, J =
.4, 4.4 Hz, 1H), 2.79 (d, J = 4.5, 1H), 2.29 (ddd, J = 15.2, 9.9, 5.5 Hz, 1H), 2.20-2.05 (m, 3H),
2.15 (s, 3H), 2.02 (s, 3H), 1.95-1.82 (m, 2H), 1.81-1.62 (m, 5H), 1.53-1.25 (m, 5H), 1.21 (d, J =
6.3 Hz, 6H), 1.16-1.12 (m, 1H) 1.14 (s, 3H), 0.79 (d, J = 6.5 Hz, 3H), 0.75 (s, 3H).
(i) Isopropyl 1β-hydroxy-7α,12α-diacetoxyketo-5β-cholanoate.
O OAc
The dibromoketone of step (g) (100 mg, 0.14 mmol) was dissolved in THF (5 mL) and
hydrogenated at ambient temperature and pressure over 5% Pd/C (15.0 mg) in the presence of
sodium acetate (38 mg, 0.425 mmol) for 5h. The catalyst was filtered through a pad of Celite
and the solvent evaporated under reduced pressure, the residue was purified by flash
chromatography (Hexanes/EtOAc 40 : 60) to afford the hydroxyketone (35 mg, 45%). H NMR
(400 MHz, CDCl ): δ 5.11 (at, J = 2.4 Hz, 1H), 5.03-5.00 (m, 1H), 4.99 (sept., J = 6.3 Hz, 1H),
4.09-4.04 (m, 1H), 2.98 (dd, J = 15.5, 13.0, 1H), 2.54 (dd, J = 14.8, 2.0 Hz, 1H), 2.39-2.29 (m,
3H), 2.22-2.04 (m, 2H), 2.11 (s, 3H), 2.07 (s, 3H), 1.94-1.64 (m, 10H), 1.48-1.24 (m, 6H), 1.22
(d, J = 6.3 Hz, 6H), 1.14 (s, 3H), 0.82 (d, J = 6.5 Hz, 3H), 0.77 (s, 3H).
(j) Isopropyl 1β,3α-dihydroxy-7α,12α-diacetoxy-5β-cholanoate.
HO OAc
Dibromo-diol of step (h) (50 mg, 0.71 mmol) in Ethanol (30 mL) containing NaOAc (11.5 mg,
0.14 mmol) and acetic acid (30 µL) was hydrogenated over Raney Nickel (8 mg) at 180 atm and
r.t. for 72h. Filtration of the catalyst over a pad of Celite , evaporation of the solvents under
reduced pressure and purification of the crude by silica gel flash chromatography (AcOEt 100%)
gave the desired diol (18 mg, 46%). H NMR (400 MHz, CDCl ): δ 5.06 (at, J = 2.5 Hz, 1H),
4.99 (sept., J = 6.3 Hz, 1H), 4.92-4.89 (m, 1H), 4.06-3.98 (m, 1H), 3.88-3.85 (m, 1H) 2.29 (ddd,
J = 15.5, 9.6, 5.6, 1H), 2.18 (dd, J = 9.5, 6.8 Hz, 1H), 2.13 (s, 3H), 2.09 (s, 3H), 1.96-1.73 (m,
8H), 1.73-1.36 (m, 13H), 1.22 (d, J = 6.3 Hz, 6H), 1.17-1.07 (m, 1H), 1.03 (s, 3H), 0.80 (d, J =
6.5 Hz, 3H), 0.77 (s, 3H).
In analogy to Example 1(g), selective hydrolysis of the acetate groups using anhydrous base
(such as sodium isopropoxide in isopropanol) yields the tetrahydroxy-isopropylester.
Example 3: Synthesis of isopropyl-1β,3α-dihydroxy-2α-bromo-7α,12α-diacetoxy-5β-cholan
oate.
(a) Isopropyl 1-epoxy-7α,12α-diacetoxy-5β-cholanoate.
O OAc
The bromide obtained in Example 2(f) (200 mg, 0.32 mmol) in THF (5 mL) containing NaOAc
(52 mg, 0.64 mmol) was hydrogenated over Raney Nickel (20 mg) at ambient temperature and
pressure for 30 minutes. The catalyst was filtered over a pad of Celite , the solvent was
evaporated under reduced pressure and the residue was dissolved in EtOAc and washed with
brine. The organic extracts were evaporated under reduced pressure and the crude residue was
triturated with diisopropyl ether to give the epoxyketone (141 mg, 81%). H NMR (400 MHz,
CDCl ): δ 5.10-5.08 (br, 1H), 5.03-4.96 (m, 2H), 3.34 (d, J = 3.8 Hz, 1H), 3.27 (d, J = 3.8 Hz,
1H), 2.70 (dd, J = 19.3, 11.9 Hz, 1H), 2.34-2.25 (m, 2H), 2.20-2.06 (m, 2H), 2.11 (s, 3H), 2.07
(s, 3H), 1.92-1.73 (m, 7H), 1.71-1.60 (m, 4H), 1.47-1.34 (m, 2H), 1.29 (s, 3H), 1.21 (d, J = 6.3
Hz, 6H), 1.34-1.25 (m, 2H), 0.81 (d, J = 6.5 Hz, 3H), 0.76 (s, 3H).
(b) Isopropyl 1β-hydroxy-2α-bromo-7α,12α-diacetoxyoxo-5β-cholanoate.
O OAc
To a solution of the epoxyketone obtained in step (a) (30 mg, 0.05 mmol) in acetic acid (0.7 mL),
LiBr (9.53 mg, 0.1 mmol) was added. After stirring at r.t. for 30 minutes the reaction mixture
was poured into water and NaHCO was added until neutral pH. The mixture was then extracted
with EtOAc and the solvents removed under reduced pressure to give the hydroxyketone (33 mg,
96%). H NMR (400 MHz, CDCl ): δ 5.13-5.10 (br, 1H), 5.03-4.93 (m, 2H), 4.54 (d, J = 8.1 Hz,
1H), 3.82 (dd, J = 7.7 Hz, 1H), 3.20 (dd, J = 16.4, 13.5 Hz, 1H), 2.38-2.12 (m, 7H), 2.10 (s, 3H),
2.09 (s, 3H), 1.96-1.61 (m, 8H), 1.41-1.23 (m, 5H), 1.22 (d, J = 6.2 Hz, 6H), 1.15 (s, 3H), 0.80
(d, J = 6.5 Hz, 3H), 0.78 (s, 3H).
(c) Isopropyl 1β,3α-dihydroxy-2α-bromo-7α,12α-diacetoxy-5β-cholanoate.
HO OAc
To a solution of the epoxyketone obtained in step (a) (50 mg, 0.091 mmol) in acetic acid (1 mL),
LiBr (16 mg, 0.18 mmol) was added. To the reaction mixture, a previously prepared solution of
sodium triacetoxyborohydride in acetic acid (obtained by adding 4.1 mg of NaBH to 0.5 mL of
acetic acid at 0°C), was added. After stirring at r.t. for 30 minutes the reaction mixture was
concentrated under reduced pressure and the residue was dissolved in EtOAc and washed with
brine, the solvent was evaporated under reduced pressure to give the product (43 mg, 75%). H
NMR (400 MHz, CDCl ): δ 5.05 (at, , J = 2.6 Hz, 1H), 4.99 (sept., J = 6.2 Hz, 1H), 4.94-4.87
(m, 1H), 4.53-4.49 (m, 1H), 4.15-4.09 (m, 1H), 3.94-3.85 (m, 1H), 2.34-2.10 (m, 6H), 2.10 (s,
3H), 2.04 (s, 3H), 1.94-1.54 (m, 10H), 1.54-1.24 (m, 5H), 1.22 (d, J = 6.2 Hz, 6H), 1.16-1.07 (m,
1H), 1.05 (s, 3H), 0.80 (d, J = 6.4 Hz, 3H), 0.74 (s, 3H).
Subsequent reduction yields the corresponding diol compound, which can be converted to the
tetrahydroxy-ester or free acid through partial or full hydrolysis, respectively.
Example 4: Synthesis of 1β,3α,7α,12α-tetrahydroxy-5β-cholanoic acid.
The diol obtained in step 1(f) (1.5 g, 2.87 mmol) was added to a mixture of MeOH/H O (3 : 2, 50
mL) containing NaOH (1.5 g, 28.7 mmol). The mixture was heated at 120 °C and, after 13h,
TLC showed the presence of a single more polar spot (Rf = 0.48, CHCl /MeOH/CH COOH 5 : 1
: 0.5). The reaction mixture was allowed to cool at r.t., and the base excess was neutralized by
adding cationic exchange resin DOWEX 50WX2, 50-100, until neutral/ slightly acidic pH. The
resin was filtered off, washed with H O/MeOH (50 : 50) and the solvent was removed under
reduced pressure to give the desired free acid-tetraol (1.1 g, 90%). White solid: m. p. = 288-290
°C, Lit (Tohma M. et al., Chem. Pharm. Bull. 1986, 34 (7), 2890-2899) = 288-290 °C. =
[α ]
+19.6 (c = 0.33 in MeOH); H NMR (400 MHz, d6-DMSO): δ 3.76 (at, J = 2.8 Hz, 1H), 3.72-
3.62 (m, 1H), 3.62-3.57 (m, 2H), 2.30-2.16 (m, 2H), 2.14-2.04 (m, 2H), 2.01-1.92 (m, 1H), 1.81-
1.57 (m, 7H), 1.49-1.11 (m, 9H), 1.01-0.92 (m, 1H), 0.91 (d, J = 6.4 Hz, 3H), 0.86 (s, 3H), 0.58
(s 3H); C NMR (101 MHz, d6-DMSO): δ 175.0, 71.4, 70.9, 66.1, 64.7, 46.1, 45.5, 41.3, 39.9,
39.2, 38.7, 37.6, 35.2, 35.1, 34.6, 31.0, 30.9, 28.6, 27.7, 27.2, 22.9, 17.3, 16.9, 12.4; IR (film): ν
-1 +
= 3370, 2922, 2858, 2359, 2342, 1705, 1377, 1184, 1027, 1033 cm ; HRMS (ES ): m/z: Calcd
for C H O (M - H): 423.2752, found: 423.2734.
24 39 6
Alternatively, the diol-diacetate-isopropylester obtained in step 2(j) (20 mg, 0.036 mmol) can be
hydrolyzed under the same conditions reported above to furnish the free acid-tetraol (13 mg,
84%), whose analytical data where superimposable to the ones of the compound obtained above.
Example 5: Synthesis of methyl 3α-hydroxy-7α,12α-diacetoxy-5β-cholenoate.
A suspension of the enone of Example 1(d) (250 mg, 0.49 mmol) and CeCl (278 mg, 0.75
mmol) in MeOH (8 mL) was cooled at -78°C and NaBH (28 mg, 0.75 mmol) was added. After
stirring at -78 °C for 30 minutes, the reaction mixture was quenched with acetone (0.5 mL) and
the solvent was evaporated under reduced pressure. The residue was diluted with EtOAc and
washed with brine. The organic phase was concentrated under reduced pressure to give the crude
material which was triturated with diisopropyl ether to give the desired allylic alcohol (244 mg,
97%). H NMR (400 MHz, CDCl ): δ 5.55 (s, 2H), 5.06 (at, J = 2.8, 1H), 4.91 (dd, J = 5.9, 3.1
Hz, 1H), 4.26-4.18 (m, 1H), 3.65 (s, 3H), 2.34 (ddd, J = 15.9, 10.6, 5.1 Hz, 1H), 2.22 (dd, J =
9.6, 6.9 Hz, 1H), 2.10 (s, 3H), 2.08 (s, 3H), 2.01-1.54 (m, 11H), 1.53-1.22 (m, 6H), 1.15-1.03 (m,
1H), 1.00 (s, 3H), 0.79 (d, J = 6.3 Hz, 3H), 0.73 (s, 3H).
Example 6: Synthesis of methyl-1β-epoxy-3α-hydroxy-7α,12α-diacetoxy-5β-cholanoate and
methyl-1α-epoxy-3α-hydroxy-7α,12α-diacetoxy-5β-cholanoate.
OAc OAc
OMe OMe
HO OAc HO OAc
1β-epoxy 1α-epoxy
The allylic alcohol obtained in example 4 (100 mg, 0.39 mmol) was dissolved in a mixture of
THF (3mL) and water (1mL), and NBS (89mg, 0.39 mmol) was added. The mixture was stirred
at r.t. for 24 h, after which time complete conversion of the starting material into two spots on
TLC corresponding to an epimeric mixture of epoxides could be observed (Hexane/EtOAc 3 : 4,
Rf = 0.38 and Rf = 0.42, respectively). The mixture was quenched with NaHSO and extracted
with EtOAc. Evaporation of the solvent afforded the crude residue which was purified by flash
chromatography (Hexanes/EtOAc 3: 4) to give the 1β-epoxide (31 mg, 30%): H NMR (400
MHz, CDCl ): δ 5.08 (at, J = 2.9, 1H), 4.86 (dd, J = 5.8, 2.9 Hz, 1H), 3.88 (dd, J = 10.8, 6.3 Hz,
1H), 3.65 (s, 3H), 3.14 (brd, J = 3.6 Hz, 1H), 3.05 (brd, J = 3.6 Hz, 1H), 2.34 (ddd, J = 15.4,
.0, 4.7 Hz, 1H), 2.22 (dd, J = 9.9, 7.0 Hz, 1H), 2.15 (s, 3H), 2.06 (s, 3H), 1.98-1.54 (m, 12H),
1.53-1.18 (m, 6H), 1.18-1.02 (m, 1H), 1.12 (s, 3H), 0.79 (d, J = 6.3 Hz, 3H), 0.75 (s, 3H).
Further elution afforded the epimeric 1α-epoxide (29 mg, 28%): H NMR (400 MHz, CDCl ): δ
.09 (at, J = 2.8, 1H), 4.85 (dd, J = 6.3, 3.6 Hz, 1H), 3.88 (dd, J = 10.8, 6.3 Hz, 1H), 3.66 (s,
3H), 3.32 (brd, J = 4.1 Hz, 1H), 2.93 (d, J = 4.1 Hz, 1H), 2.35 (ddd, J = 15.5, 10.3, 5.6 Hz, 1H),
2.21 (dd, J = 8.9, 2.6 Hz, 1H), 2.14 (s, 3H), 2.06 (s, 3H), 1.98-1.54 (m, 12H), 1.53-1.18 (m, 7H),
1.07 (s, 3H), 0.82 (d, J = 6.3 Hz, 3H), 0.75 (s, 3H).
Example 6: Synthesis of 1β,3β,7α,12α-tetrahydroxy-5β-cholanoic acid.
(a) Methyl 1β,3β-dihydroxy-7α,12α-diacetoxy-5β-cholanoate.
Hydroxyketone obtained according to Tohma M. et al, Chem. Pharm. Bull. 1986, 34 (7), 2890-
2899 (100 mg, 0.19 mmol) was reduced in the presence of NaBH (7.5 mg, 0.19 mmol) in THF
(4 mL) at r.t.. After 10 minutes the solvent was evaporated under reduced pressure and the
residue was diluted with EtOAc and washed with brine to afford the crude material consisting of
two spots on TLC in about 1 : 1 ratio corresponding to the desired 3β epimer (Rf = 0.48, EtOAc
100%) and the 3α epimer (Rf = 0.25, EtOAc 100%). Purification by flash chromatography
(Hexanes/EtOAc 40 : 60) afforded the desired 3β-diol (40 mg, 39.8 %). H NMR (400 MHz,
CDCl ): δ 5.07 (at, J = 2.8, 1H), 4.94 (dd, J = 6.3, 3.6 Hz, 1H), 4.17-4.13 (m, 1H), 3.78-3.74 (m,
1H), 3.66 (s, 3H), 2.40-2.14 (m, 2H), 2.10 (s, 3H), 2.08 (s, 3H), 2.03-1.64 (m, 8H), 1.63-1.54
(m, 6H), 1.53-1.23 (m, 4H), 1.18-1.00 (m, 2H), 1.11 (s, 3H), 0.81 (d, J = 6.3 Hz, 3H), 0.75 (s,
3H).
(b) 1β,3β,7α,12α-tetrahydroxy-5β-cholanoic acid.
HO OH
The 3β-diol obtained in step (a) (40 mg, 0.077 mmol) was added to a mixture of MeOH/H O (3 :
2, 3 mL) containing NaOH (31 mg, 0.77 mmol). The mixture was heated at 120 °C and, after 13h
it was cooled to r.t., and the base excess was neutralized by adding cationic exchange resin
DOWEX 50WX2, 50-100, until neutral/ slightly acidic pH. The resin was filtered off, washed
with H O/MeOH (50 : 50) and the solvent was removed under reduced pressure to give the
desired 1β,3β-tetraol (27 mg, 83%). H NMR (300 MHz, CD OD): δ 4.06 (at, J = 2.8, 1H), 3.94
(at, J = 2.4 Hz, 1H), 3.82 (dd, J = 6.0, 3.2 Hz, 1H), 3.73-3.70 (m, 1H), 2.64 (at, J = 14.2 Hz,
1H), 2.33 (ddd, J = 14.8, 9.9, 4.8 Hz, 1H), 2.20 (dd, J = 9.4, 7.0 Hz, 1H), 2.16-1.71 (m, 12H),
1.71-1.22 (m,6H), 1.19-1.02 (m, 1H), 1.07 (s, 3H), 1.01 (d, J = 6.3 Hz, 3H), 0.73 (s, 3H).
Example 7: Repression of ROR gamma activity using a luciferase assay.
1β,3α,7α,12α-Tetrahydroxy-5β-cholanoate (herein also called tetraol or tetraol compound)
was tested for its ability to inhibit transcriptional activity of RORγ using a dual luciferase assay
(Figure 1), in which activation of the matrix-metalloproteinase 3 (MMP3) promoter, which is a
target gene of RORγ, by RORγ was tested in the presence of different concentrations of
compound 1. 3T3L1 Preadipocyte cells were transfected with the reporter gene an expression
vector for RORγ as well normalization vector expressing renilla luciferase. Cells were treated
after infection with different amounts of RORγ ranging from 1 to 25 nM. Cells were lysed 24h
after treatment with the tetraol compound and firefly as well as renilla luciferase activity was
measured. The repression of RORγ activity was calculated from the ratio of firefly over renilla
luciferase. Analysis of the tetraol compound in an activity assay shows a dose dependent
reduction of RORgamma activity. This is illustrated in Figure 2, which clearly shows that the
relative inhibition (RI, y-axis) is decreasing with increasing concentration of the tetraol
compound (conc in nM, x-axis).
Example 8: In vivo prevention efficacy.
To test the in vivo efficacy of the tetraol compound mice were fed a high fat diet (60% calories
derived from fat) for 6 weeks. The diet was supplemented with 0.1% or 0.01 % of the tetraol
compound (A and B, respectively, in Figure 3). Mice receiving high fat diet only (E in Figure 3)
and mice receiving high fat diet supplemented with 0.1% cholic acid (C in Figure 3) and 0.01%
cholic acid (D in Figure 3), respectively served as control.
Figure 3 clearly shows, that treatment of mice with the tetraol compound led to a dramatic
improvement in insulin sensitivity at either concentration, as measured by an insulin tolerance
test.
Example 9: In vivo therapeutic efficacy.
To test the in vivo therapeutic efficacy of tetraol compound mice were fed a high fat diet (60%
calories derived from fat) for 6 weeks. Afterwards the obese/insulin resistant mice were put on a
diet supplemented with either 0.01 % of tetraol or 0.01 % of cholic acid for either 6 or 12 weeks
(0.01% tetraol and 0.01% CA, respectively, in Figures 4 and 5).
Figures 4 and 5 clearly show, that treatment of obese insulin resistant mice with tetraol led over
time to a dramatic improvement in insulin sensitivity, as measured by circulating glucose (Fig. 4)
and insulin levels (Figure 5): gluc = glucose levels in mM; ins = insulin levels in pg/ml.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise,
reference to such external documents is not to be construed as an admission that such documents,
or such sources of information, in any jurisdiction, are prior art, or form part of the common
general knowledge in the art.
In the description in this specification reference may be made to subject matter that is not within
the scope of the claims of the current application. That subject matter should be readily
identifiable by a person skilled in the art and may assist in putting into practice the invention as
defined in the claims of this application.
Claims (16)
1. Use of a compound having formula II or a formula IIa and pharmaceutically acceptable salt or stereoisomers thereof, in the manufacture of a medicament for the treatment or prevention of disorders, diseases or conditions responsive to the modulation of the ROR gamma receptor, which are type II diabetes and diseases, disorders and conditions that are related to type II diabetes, selected from hyperglycemia, low glucose tolerance, insulin resistance, obesity, lipid disorders, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, atherosclerosis, vascular restenosis, irritable bowel syndrome, inflammatory bowel disease, including Crohn's disease and ulcerative colitis, other inflammatory conditions, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, nephropathy, neuropathy, Syndrome X, and ovarian hyperandrogenism (polycystic ovarian syndrome), in a subject in need thereof, II IIa wherein R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R , wherein 1 2 a a a b a a b R and R are independently of each other H or (C1-6)alkyl, or R , R form together with a b 1 2 the C-atoms to which they are linked an epoxy group; R2’ is H, hal, R , R , R , R , are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo, 3 4 5 6 a a a b a a b thio wherein R and R are independently of each other H or (C1-6)alkyl; L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted or substituted by at least one CN, hal, OH, NR R , COOR , NO , and wherein one or more of the non-adjacent a b a 2 CH groups may independently be replaced by a group selected from –O-, -CO-, -CO-O-, - O-CO-, -NR -, -NR -CO-, -CO-NR -, -CH=CH-, -C≡C-, wherein R and R are independently a a a a b of each other H or C(1-6)alkyl, X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each a a a b c a c a b other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R , c 2 n 2 a 2 p 3 a wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl; m is 0 to 5, and wherein R and R are –OR , wherein R is H or C(1-6)alkyl. 3 6 a a
2. Use according to claim 1, wherein L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one or more of the non-adjacent CH groups may independently be replaced by a group selected from –O-, -CO-, - CO-O-.
3. Use according to claims 1 or 2, wherein X is H, -OR , -COOR , -CONR R , wherein R is H a c a c a or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-CH -CO R or -NH-(CH ) -SO R , wherein R c 2 2 a 2 2 3p a a is -H or -(C1-6)alkyl.
4. Use according to claims 1 or 2, wherein -L-X is –(C1-6)alkyl-COOR .
5. Use according to claims 1 or 2, wherein R2 is H or hal.
6. Use according to claim 1 having formula IIIg or formula IIIi and IIIi , and all pharmaceutically acceptable salts or stereoisomers thereof, R O R IIIg wherein R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , wherein R and R are independently of 1 a a a b a a b a b each other H or (C1-6)alkyl, or R forms together with R and the C-atoms to which R , R 1 2 1 2 are linked to an epoxy group; R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , wherein R and R are independently of 2 a a a b a a b a b each other H or (C1-6)alkyl, or R forms together with R and the C-atoms to which R , R 2 1 1 2 are linked to an epoxy group; R , R are independently of each other H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo, thio, 4 5 a a a b a a b wherein R and R are independently of each other H or (C1-6)alkyl; R is H or hal, L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one or more of the non-adjacent CH groups may independently be replaced by a group selected from –O-, -CO-, - CO-O; X is H, -ORa, -SRa, -NRaRb, -COORc, -CONRaRc; wherein Ra and Rb are independently of each other H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, -NH-(CH ) -CO R or -NH-(CH ) -SO R , c 2 n 2 a 2 p 3 a wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl; R is H or C(1-6)alkyl, m is 0 to 5.
7. Use according to claim 6, wherein R is H, -OR , -NR R , or wherein R is H or hal, or 1 a a b 2 wherein R , R are independently of each other H, oxo, -OR , -NR R , wherein R and R 4 5 a a b a b are independently of each other H or (C1-6)alkyl.
8. Use according to claim 6, wherein R or R or both R and R , are -OR , wherein R is H or 1 4 1 4 a a (C1-6)alkyl.
9. Use according to claim 1 having formula V or formula Va and Vb and all pharmaceutically acceptable salts or stereoisomers thereof, R O OR L X L X OR OR R O OR R O OR a a a a (H) m R ' R ' Va Vb wherein R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , wherein R and R are independently of 1 a a a b a a b a b each other H or (C1-6)alkyl, or R forms together with R and the C-atoms to which R , R 1 2 1 2 are linked to an epoxy group; R is H or hal, or R forms together with R and the C-atoms to which R , R are linked to an 2 2 1 1 2 epoxy group; R is H or hal, R is H, hal, -OR , -SR , -NR R , -COOR , -CONR R , oxo, thio, wherein R and R are 4 a a a b a a b a b independently of each other H or (C1-6)alkyl, L is a straight-chain or branched C(1-12)alkyl; X is H, -OR , –COOR , -CONR R , wherein R is H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, - a c a c a c NH-(CH ) -CO R or -NH-(CH ) -SO R , wherein n, p is 1, 2, or 3 and R is -H or -(C1- 2 n 2 a 2 p 3 a a 6)alkyl, and R is H or C(1-6)alkyl, m is 0 to 5.
10. Use according to claim 9, wherein R is H, -OR , -NR R , or wherein R is H, oxo, -OR , - 1 a a b 4 a NRaRb, wherein Ra and Rb are independently of each other H or (C1-6)alkyl.
11. Use according to claim 9 wherein R1 or R4 or both R1 and R4, are -ORa, wherein Ra is H or (C1-6)alkyl.
12. Use according to claim 1 having formula VIa or formulae VIa and VIa , and all pharmaceutically acceptable salts or stereoisomers thereof, wherein L is a straight-chain or branched C(1-12)alkyl, which is unsubstituted and wherein one or more of the non-adjacent CH groups may independently be replaced by a group selected from -O-, -CO-, - CO-O-, R is H or C(1-6)alkyl, X is H, -OR , -SR , -NR R , -COOR , -CONR R ; wherein R and R are independently of each a a a b c a c a b other H or (C1-6)alkyl and Rc is -H, -(C1-6)alkyl, -NH-(CH2)n-CO2Ra or -NH-(CH2)p-SO3Ra, wherein n, p is 1, 2, or 3 and R is -H or -(C1-6)alkyl,
13. Use according to claim 12, wherein L is straight-chain or branched C(l-6)alkyl or wherein X is is H, -OR , -COOR , -CONR R ; wherein R is H or (C1-6)alkyl and R is -H, -(C1-6)alkyl, a c a c a c -NH-(CH ) -CO Ra or -NH-(CH ) -SO R , wherein n, p is 1, 2, or 3. 2 n 2 2 p 3 a
14. Use according to any one of claims 1 to 13, wherein the compound is in form of a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier, optionally comprising at least one further therapeutically active agent.
15. Use according to any one of claims 1 to 13, wherein the disorders, diseases or conditions responsive to the modulation of the ROR gamma receptor, which are the diseases, disorders and conditions that are related to type II diabetes, are impaired glucose tolerance, insulin resistance and hyperglycemia.
16. A use according to claim 1, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11007610.6 | 2011-09-19 | ||
EP11007610 | 2011-09-19 | ||
PCT/EP2012/068332 WO2013041519A1 (en) | 2011-09-19 | 2012-09-18 | Ror gamma modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ620485A NZ620485A (en) | 2016-04-29 |
NZ620485B2 true NZ620485B2 (en) | 2016-08-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2758060B1 (en) | Ror gamma modulators for treating diabetes ii complications | |
US11072602B2 (en) | Antidiabetic heterocyclic compounds | |
US10676458B2 (en) | Antidiabetic bicyclic compounds | |
EP3076959B1 (en) | Antidiabetic bicyclic compounds | |
WO2015119899A1 (en) | Antidiabetic compounds | |
US11225471B2 (en) | Antidiabetic bicyclic compounds | |
EP2145884B1 (en) | Indoledione derivative | |
US20160287609A1 (en) | Ror gamma modulators | |
NZ620485B2 (en) | Ror gamma modulators |